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1General InTroduCTIon
Glaucoma is a heterogeneous group of progressive optic neuropathies charac-
terised by an accelerated degeneration of retinal ganglion cells (RGCs) and their 
axons, resulting in a typical appearance of the optic nerve head and a matching 
pattern of irreversible visual field loss.1-3
Anatomy
The optic nerve connects the eye with the brain. The optic nerve leaves the eye at 
the optic nerve head (ONH), also referred to as optic disc because of its discoid 
shape when viewed from anteriorly. The optic nerve is formed by approximately 
one million nerve fibers. Before the axons converge in the ONH, they comprise 
the retinal nerve fiber layer (RNFL), which is the innermost layer of the retina. Like 
the retinal bloodvessels, the axons forming the RNFL follow an arcuate pattern 
towards the ONH. The ONH is about 1.5mm in diameter and vertically oval. The 
convergence of the axons, travelling from the RNFL to the optic nerve, forms a rim 
of neuroretinal tissue and a central depression, known as the cup.3 The neuroretinal 
rim is thickest in the inferior region, followed by the superior, nasal and temporal 
regions, following the ISNT-rule.4 In glaucoma, an increased loss of retinal ganglion 
cells and its axons occurs, leading to a typical excavation of the ONH and the 
subsequent loss and thinning of the retinal nerve fiber layer.
Figure 1 The schematic drawing on the left shows a cross-section of a human eye. The photograph 
on the right presents a anterior-to-posterior view on the retina, showing the macula, the retinal vas-
culature and the optic nerve head.
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1 Epidemiology
When left untreated, glaucoma can lead to severe visual field loss and therefore 
progressive loss of visual function. Worldwide, glaucoma is the second leading 
cause of blindness, after cataract, whereas cataract is a potentially reversible dis-
ease and glaucoma leads to irreversible blindness.5 Approximately 12% of all blind-
ness is due to glaucoma.5 As glaucoma is an age-related disease, the number of 
people affected by glaucoma will rise in the upcoming years, due to the increasing 
population aged 50 years and older. According to calculations by Quigley and Bro-
man6, in 2020, 79.6 million people worldwide will have glaucoma. The prevalence 
among people of European descent aged 40 years and older varies between 1.1 
and 2.1%, leading to an estimated prevalence of (open angle) glaucoma in the 
Netherlands somewhere between 180.000 and 360.000.7-10
Classification of Glaucoma
Traditionally, glaucoma has been classified as open angle or closed angle glau-
coma and as primary or secondary glaucoma. The first classification is based on the 
anatomy of the anterior chamber angle and is mainly interesting from a treatment 
point of view. Primary glaucoma refers to glaucomatous damage when there is no 
identifiable underlying ocular or systemic disorder, whereas secondary glaucoma 
refers to those glaucomas caused by an ophthalmological or extraocular disease, 
drugs or treatment. Primary open angle glaucoma (POAG) is the most common 
form of glaucoma in Western countries.3
Risk factors
Glaucoma is a multifactorial disease with increased intraocular pressure (IOP) as 
the most important risk factor. An increased or highly fluctuating IOP is related to a 
higher prevalence, incidence and progression of POAG.11 Historically, an elevated 
IOP was included in clinically defining glaucoma. However, approximately 20-75% 
of all patients with POAG have IOPs within the normal range, a condition referred 
to as ‘normal tension glaucoma’.11 However, an increased IOP does not neces-
sarily lead to glaucomatous damage. Eyes with an increased IOP but without any 
signs of an optic neuropathy or any visual field loss are referred to as having ocular 
hypertension.1 Other risk factors for POAG include increased age, African descent, 
a positive family history of glaucoma, myopia, a thinner cornea, and a reduced 
perfusion pressure.1;2;11 The role of various systemic factors, such as diabetes, sys-
temic hypertension, migraine and ischemic vascular diseases, in the development 
of glaucoma has been widely debated, but the evidence is still inconclusive.11
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1Pathophysiology
The exact pathophysiology of glaucoma is not fully understood, although the death 
of RGCs is related to the level of increased IOP3 and a reduced ocular blood sup-
ply.12 Although no obstruction of the trabecular meshwork can be seen by gonios-
copy in patients with POAG, the resistance to aqueous outflow is increased.3 When 
the level of IOP rises above physiological levels, the pressure gradient across the 
lamina cribrosa, an array of perforated connective tissue sheets through which the 
optic nerve fibers transverse to form the optic nerve, also increases. The increased 
IOP leads to mechanical stress of the lamina cribrosa and the retinal ganglion cell 
axons. The vascular factor causing glaucoma is a reduced retinal or ONH blood 
supply, leading to local ischemia and/or hypoxia and subsequent death of RGCs 
and optic nerve fibers. Various other contributing factors include a blockade of 
axonal protein transport by increased IOP, poorly functioning cellular pumps and 
glutamate transporters, inflammatory cytokines, aberrant immunity and apoptosis 
of RGCs secondary to initial optic nerve injury.3;12
Treatment
Glaucoma care in Europe aims to enhance the patient’s health and quality of life by 
preserving visual function without causing untoward effects from treatment.1 Of all 
risk factors that play a role in glaucoma, the IOP is presently the only one that can 
be altered therapeutically. Lowering IOP has been shown to slow down the pro-
gression of glaucoma.13;14 Treatment options are either pharmaceutically (eyedrops 
or oral medication) or surgically (laser surgery, filtering surgery or implant surgery). 
Topical treatment decreases the IOP by reducing the aqueous production and/
or increasing the trabecular or uveoscleral outflow. Surgical treatment aims for a 
permanent IOP reduction by increasing the aqueous outflow.
Ocular Hypertension
Ocular hypertension (OH) refers to those eyes with an elevated IOP without an 
optic neuropathy or visual field loss.1 The prevalence of OH is 4.5% in whites aged 
40 years and older.15 The higher the IOP, the higher the risk of developing glau-
coma.16 Several large studies have presented conflicting results whether or not 
to treat ocular hypertension. The Ocular Hypertension Treatment Study (OHTS) 
found a 50% reduction of the risk to develop glaucoma by topical medication.17 
The European Glaucoma Prevention Study (EGPS) shows no advantage of dor-
zolamide against placebo in preventing or delaying the onset of glaucoma.18 The 
European Glaucoma Society therefore advises to assess each patient individually 
when deciding whether or not to treat.1
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1
Diagnosing Glaucoma in daily care
To date, there is still no technique that measures the exact nature of the disease (the 
death of the RGCs and their axons). All techniques developed in the past decades in-
directly measure the functional or structural loss caused by the lost RGCs and axons. 
This means that up till now we are facing challenging glaucoma care, searching for 
a way to diagnose and monitor glaucoma which is most objective, patient friendly, 
quantitative and qualitative and highly sensitive and specific for glaucoma.
Figure 2 Illustration of the 3 most commonly explored features in daily glaucoma care. The left col-
umn shows the measurement techniques of eye pressure, visual field testing and ophthalmoscopy, 
respectively. The right column shows what the clinician views to assess these clinically relevant features.
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1In daily glaucoma care, 3 main parameters are followed to diagnose and moni-
tor glaucoma. Firstly, the IOP is measured. Usually an individual target pressure 
is determined, which is the maximal IOP that the eye can handle in order not to 
progress. Secondly, the function of the eyes is determined by measuring the visual 
field of each. Due to glaucoma, patients lose their visual field, characteristically 
firstly the mid-peripheral visual field2, slowly increasing to the centre of the visual 
field. This functional loss is measured with (standard automated) perimetry. And 
thirdly, structural damage is assessed by measuring the optic nerve head (ONH; 
also referred to as optic disc). With increasing loss of retinal ganglion cells and 
its axons, the ONH becomes more and more excavated. The typical cupping of 
the ONH and the subsequent loss of thinning of the retinal nerve fiber layer are 
structural changes which nowadays are measured by several imaging techniques, 
such as optical coherence tomography, confocal scanning laser ophthalmoscopy 
and scanning laser polarimetry.
Because this thesis addresses the diagnosis and monitoring of glaucoma, several 
techniques for measuring glaucoma and its progression will be presented below 
further in detail.
Visual Field
Standard Visual Field Testing
The mid-peripheral visual field in glaucoma is tested by perimetry. The Humphrey 
Field Analyzer (HFA, Carl Zeiss Meditec, CA, USA) is the most commonly used pe-
rimeter, both clinically and scientifically. In perimetry, the visual function is assessed 
by determining the retinal differential light sensitivity (DLS) to white light at various 
locations in the central retina within 24 or 30 degrees of fixation. The DLS is most 
commonly assessed in 54 or 76 locations, which are compared with age-corrected 
normative data and summarized and translated into global indices such as the 
mean deviation (MD) or the visual field index (VFI). Standard automated perimetry 
(SAP), which employs a white stimulus on a white background, is the most com-
monly used visual field test in glaucoma. Glaucomatous visual field abnormalities 
follow a nerve fiber bundle pattern.19 Typically glaucomatous visual field defects 
are paracentral scotomas, arcuate (Bjerrum) scotomas, nasal steps, altitudinal 
defects, and temporal wedges.2;3;19;20 A generalized depression in sensitivity may 
also be caused by glaucoma, but appears more frequently due to media opacities 
and miosis.19 In end-stage glaucoma only a central island of vision (and a temporal 
remainder) is retained at the visual field.20
In clinical care, visual field testing is often used for monitoring glaucoma. Sev-
eral progression analysis strategies have been developed, classified into either 
14
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1 event- or trend-based analyses.
21 In event-based analyses, a change that exceeds 
the measurement variability may be considered as progression. In trend-based 
progression analyses, a measurement series are analysed over time and change 
is defined by a significant rate of progression. Nowadays, the HFA incorporates 
progression analysis software (Guided Progression Analysis, GPA, HFA-II-i, Soft-
ware Version 4.2, CZM, Dublin, CA, USA), providing an easy accessible progression 
analysis in daily glaucoma care.
Despite the typical abnormalities of a glaucomatous visual field as described 
before and despite many efforts towards standardizing these abnormalities, there 
are no generally approved and used criteria for glaucomatous visual field defects, 
nor for glaucomatous progression.21-24 Perimetry has a number of drawbacks that 
preclude its use as a criterion for glaucoma. SAP is a subjective measurement, 
because its outcome largely depends on a patient’s response to the stimulus, 
which varies both during and between tests.25-27 Fatigue, inability to understand 
the instructions and a learning effect affect the reliability of a test, limiting the 
reproducibility of the test.
Histopathological studies have shown that 25-50% of the RGCs have to be dam-
aged, before visual field defects become apparent.3;28;29 This implies that structural 
damage precedes functional damage, a phenomenon which has been confirmed 
by several in vivo studies.3;30-35
Other forms of visual field testing
Selective perimetry isolates specific retinal ganglion cell populations. There are 
three major subtypes of RGCs in the retina: the magnocellular cells, the parvo-
cellular cells and the small bistratified cells. Selective perimetry is thought to 
identify glaucoma earlier than standard visual field testing. With short wavelength 
automated perimetry (SWAP), the small bistratified cells are tested by employing a 
blue stimulus against a yellow background. The blue background saturates the me-
dium- and long-wavelength sensitive cones, whereas the short-wavelength cones 
are activated by the yellow stimulus. In this setting, only the short-wavelength 
pathway is tested and up till now is thought to detect glaucomatous defects earlier 
than testing all pathways at the same time, as happens in SAP.36-40
Frequency-doubling technique (FDT) targets the magnocellular cells by pre-
senting a stimulus with a high temporal frequency and a low spatial frequency.20 
The reason why these techniques show glaucomatous defects earlier than SAP is 
unknown. In daily glaucoma care, these selective perimetry tests are performed 
considerably less often than SAP, because of the higher measurement variability, 
the learning effects and because it is more demanding for the patient.41-43
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1Optic nerve head assessment by ophthalmoscopy or stereophotography
The optic nerve head (ONH) is the site where structural changes are most visually 
apparent. Characteristic glaucomatous ONH changes are increased cupping or 
excavation, notching or thinning of the neuroretinal rim, disc hemorrhages, asym-
metry of the amount of optic nerve cupping between the two eyes of the patient 
and baring of the circumlinear vessels.1;3;44 In daily glaucoma care, the clinician 
subjectively assesses the ONH by direct or indirect ophthalmoscopy, which remains 
a cornerstone for diagnosing and monitoring glaucoma. However, discriminating 
between healthy and glaucomatous ONHs has been shown to be difficult for oph-
thalmologists and even glaucoma specialists.45-51
Imaging techniques
The typical cupping of the ONH and the subsequent loss of thinning of the retinal 
nerve fiber layer are structural changes which can be measured by several imaging 
techniques, such as optical coherence tomography (OCT), confocal scanning laser 
ophthalmoscopy (CSLO) and scanning laser polarimetry (SLP).
Scanning Laser Polarimetry
SLP is a clinical non-invasive, noncontact technique that allows indirectly assessing 
the thickness of the retinal nerve fiber layer (RNFL). SLP uses the phenomenon of 
form birefringence, which occurs in tissue that is composed of parallel structures, 
each of which is of a smaller diameter than the wavelength of light used to image 
it.3 SLP measures the retardation (phase shift) of a polarised laser light passing 
through the eye onto the RNFL, of which each microtubule within the individual 
nerve fibers creates birefringence. The greater the number of microtubules, the 
greater the retardation of the polarised laser light, indicating the presence of more 
tissue. There are more tissues in the eye, such as the cornea, the lens and the 
layer of Henle in the fovea that can exhibit form birefringence.52-54 Since 1993, SLP 
Figure 3 Optic nerve head and retinal nerve fiber layer assessment techniques: stereophotography 
(A), scanning laser polarimetry (B) and confocal scanning laser ophthalmoscopy (C), respectively.
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1 has been commercially available and since then it has evolved through several 
types of SLP to the currently available GDxVCC55 and GDxECC56 (GDx, Carl Zeiss 
Meditec, Dublin, CA, USA). In the currently available SLP devices, the birefringence 
of other structures than the RNFL is individually compensated (by the so-called 
variable (VCC) and enhanced (ECC) corneal compensation) per individual eye. 
These enhancements of the techniques were shown to have an improved ability to 
discriminate between healthy and glaucomatous eyes.57-59
SLP indirectly measures the thickness of the RNFL around the ONH and presents 
this in a 20 by 20 degrees colour-coded retardation map. The thickness of the 
RNFL is summarised in several parameters, which are calculated within a circular 
band (between 2.4mm and 3.2mm, respectively) around and centred on the ONH. 
The Nerve Fiber Indicator (NFI) is a support vector machine derived classifier of 
the entire RNFL thickness, which was trained specifically to discriminate between 
healthy and glaucomatous eyes. The NFI provides a single number between 0 and 
100 representing the overall integrity of the RNFL, related to the likelihood that the 
polarimetric retinal nerve fiber layer map is abnormal.60
Its diagnostic accuracy, reproducibility and its ability to monitor glaucoma has 
proven SLP to be a solid measure of structure in glaucoma, to be one of the devices 
most used in daily clinical care to diagnose and monitor glaucoma.57;61-63
Confocal scanning laser ophthalmoscopy
CSLO allows layer-by-layer imaging to measure the topography of the ONH.64 This 
technique is commercially available as the Heidelberg Retina Tomograph (HRT; 
Heidelberg Engineering GmbH, Dossenheim, Germany). This technique quantifies 
the area of the optic disc cup and neuroretinal rim, based on the reflectivity of the 
retinal surface. It measures the intensity of light reflected off the retinal surface at 
subsequent depths of focus.65 The HRT calculates several maps (i.e. a color-coded 
topography map) and parameters (i.e. the retinal surface height and the neuroreti-
nal rim area). CSLO has been shown to provide reasonable reproducibility66 and a 
fairly good diagnostic accuracy67;68 and therefore measurements can be evaluated 
longitudinally to assess whether the glaucoma is stable or progressing.
Optical coherence tomography
OCT was first described in 1991 by Fujimoto and coworkers.69 OCT enables in 
vivo visualisation of the tissue microstructure through a non-invasive, noncontact 
high resolution imaging technique. OCT generates a cross-sectional and three-
dimensional image of the retina by measuring echo time delay of backscattered 
light. It uses interferometry, a phenomenon in which the time delay from light 
reflected from inside the tissue is measured by correlating it with light that has 
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1travelled a known reference path. Since its introduction in daily clinical care in 1995, 
OCT has been increasingly used as a diagnostic tool for several retinal diseases as 
well as diseases of the ONH. The technique has been further developed from time-
domain OCT, in which a reference mirror was mechanically moving, to spectral-
domain OCT (SD-OCT), in which a fixed mirror was used and a spectrometer was 
introduced to decode the spectral signature in light. This development decreased 
the imaging time and therefore motion artefacts, and increased the axial resolution 
from 8-10 µm to 5-7 µm.70;71 Nowadays, SD-OCT is widely used in daily clinical care 
for diagnosing and monitoring retinal as well as glaucomatous abnormalities.
For the assessment of glaucoma, the thickness of the RNFL as well as the shape 
of the ONH can be determined with OCT. Software algorithms have been devel-
oped to analyse the images by segmentation of the specific retinal layers. By this, 
the thickness of the RNFL is calculated at, for instance, a circular band around and 
centred on the ONH, as is used in SLP as well. Several companies have developed 
their SD-OCT with their own developed hardware and software, with promising 
good diagnostic accuracy, but without being interchangeable. Figure 4 shows an 
example of one of the SD-OCT devices, currently commercially available.
Progression analysis
To monitor glaucoma, up till now, a clinician needed to compare several measure-
ments by hand. Nowadays, progression analysis software has been developed for 
visual fields and all imaging techniques. Most analyses use both event based and 
trend based analyses. In event based analyses, a measurement is compared with 
the baseline measurement(s), assessing whether there has been any statistically 
Figure 4 Example of spectral domain optical coherence tomography (OCT). The photograph pres-
ents the Spectralis OCT (Heidelberg Engineering, Dossenheim, Germany) and its (cross-sectional) 
images of the retina, showing the macula (upper image) and the optic nerve head (lower image).
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1 significant change. In trend based analyses, a linear regression model is most often 
used to detect progression, quantifying the rate of change, informing us about any 
potential visual disability in the future.19 Glaucoma develops in several ways, dif-
fusely or focally, slow or fast. Therefore, these several analyses are complementary 
to each other to discriminate between measurement variability or progression.19 
Figure 5 shows an example of progression analyses by visual field and SLP.
Figure 5 Progression analyses of scanning laser polarimetry (left) and visual field testing (right) of 
the same patient. SLP shows evident progression by all analyses, presented by the red dots above 
and red areas below. Visual field testing shows a minor decrease, but significant, in the visual field 
index (VFI).
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1ouTlIne of ThesIs
The objective of the research presented in this thesis was to evaluate various tech-
niques used in daily glaucoma practice to diagnose and monitor glaucoma. This 
has been established by incorporating several analyses on conversion from ocular 
hypertension to glaucoma, using measures of function and structure. Furthermore, 
we also analysed (progressing) glaucomatous eyes by the techniques used most 
frequently in daily practice and by the newest clinically used technique, i.e. optical 
coherence tomography.
The first 4 chapters of this thesis present several outcomes of a large randomised 
controlled trial, set up at the Rotterdam Eye Hospital in Rotterdam, the Nether-
lands. A total of 416 subjects with ocular hypertension (OH) participated in this 
trial, in which they were randomly allocated to either topical IOP-lowering therapy 
or placebo eyedrops. Every half-year they were measured with several instruments 
to monitor the course of the IOP, the appearance of the optic disc and the visual 
field. In chapter 2, the outcome over time of the visual field, measured by Standard 
Automated Perimetry (SAP) and Short Wavelength Automated Perimetry (SWAP), 
is presented. The main question that will be explored/answered is which of these 
two visual field tests detects the conversion to glaucoma firstly.
In chapter 3, the use of commercially available progression analyses are incorpo-
rated to present the amount of eyes converted from OH to glaucoma. The analyses 
of SAP are compared to those of Scanning Laser Polarimetry (SLP), measured by 
the GDx with variable corneal compensation (VCC) and with enhanced corneal 
compensation (ECC).
Chapter 4 presents the outcome of the large randomised controlled trial into 
the effect of beta-blockers to prevent or delay the onset of conversion from OH to 
glaucoma. In this chapter, defining conversion from OH to glaucoma is based on 
the analyses described in Chapter 3.
In chapter 5 & 6, we present data on judging optic discs by various eyecare 
professionals by assessing stereoscopic ONH photographs in diagnosing (chapter 
5) and monitoring (chapter 6) glaucoma. Chapter 6 presents the outcome of a trial 
amongst glaucoma specialists of 11 European countries into matching the optic 
disc to a visual field. In chapter 5, progression analyses of glaucomatous eyes are 
presented, comparing the outcome of analyses of the visual field and the appear-
ance of the optic disc, as it is monitored in daily glaucoma care.
Chapter 7 & 8 both describe new approaches to the use of optical coherence 
tomography (OCT). In chapter 7, a newly described phenomenon is presented. 
A temporary change in the appearance of the retinal nerve fiber layer (RNFL) in 
OCT is described in 7 glaucomatous eyes. In chapter 8, a different approach into 
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1 measuring glaucoma with OCT is presented, introducing a new parameter, the 
attenuation coeffi cient.
Finally, chapter 9 presents a general discussion of the described research in 
diagnosing and monitoring glaucoma, as well as future perspectives on this matter.
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absTraCT
Purpose. Short wavelength automated perimetry (SWAP) has been claimed to 
predict conversion to glaucoma 3-4 years before standard automated perimetry 
(SAP) defects occur. Our purpose was to compare the moment of glaucomatous 
conversion between SWAP and SAP.
Design. Prospective, longitudinal follow-up study.
Participants. Four hundred and sixteen subjects with ocular hypertension (intra-
ocular pressure ≥22 and ≤32 mmHg and normal visual fields).
Methods. A Humphrey Field Analyser (24-2 program) was used to perform both 
SWAP and SAP. All participants were tested once every half year during seven 
to ten years or until the onset of conversion (study endpoint). The conversion to 
glaucoma was defined as a reproducible glaucomatous visual field defect in SAP.
Main outcome measures. The moment of onset of a reproducible defect in SAP 
was compared to that in SWAP.
Results. Of the 416 initial participants, 24 eyes of 21 subjects showed conversion 
in SAP. Of these eyes, 22 did not show earlier conversion in SWAP than in SAP. SAP 
even showed earlier conversion than SWAP in 15 cases. In only 2 eyes did SWAP 
show earlier conversion by up to 18 months.
Conclusions. Our results do not support the notion that SWAP generally predicts 
conversion to glaucoma in SAP. Instead, SAP appears to be at least as sensitive to 
conversion as SWAP in a large majority of eyes.
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InTroduCTIon
Glaucoma is one of the main causes of blindness.1;2 Ocular hypertension (OH) has 
been recognized as an important risk factor in the development of primary open 
angle glaucoma (POAG).3 Conversion to or progression of POAG can be slowed by 
reducing the increased intraocular pressure.4-6 Follow-up of subjects with OH and 
POAG is usually done by a combination of tests, including standard automated 
perimetry (SAP), which is the current clinical standard of measuring glaucomatous 
functional loss. To measure early glaucomatous loss, it has been suggested that 
short-wavelength automated perimetry (SWAP) is more sensitive than SAP.7-11
In 1993, Sample et al.11 presented a small group of conversions to glaucoma, 
which showed substantially more prominent glaucomatous defects on SWAP 
than on SAP. In addition, Johnson et al.8 demonstrated that SWAP may predict 
conversion to glaucoma 3-4 years earlier than SAP, which was confirmed by other 
studies.7;10 It is unclear why SWAP shows these early glaucomatous defects prior to 
SAP. Because the incidence-rates of glaucomatous defects in both SAP and SWAP 
appear to be the same, Demirel and Johnson7 proposed that they monitor the 
same underlying disease.
Despite these reported advantages of SWAP over SAP, SWAP is relatively 
time-consuming, and more demanding to the subject taking it. There also is an 
increased variability within12 and between13 subjects, as well as greater long-term 
fluctuations14 compared with SAP. Hutchings et al.14 therefore concluded that 
more sophisticated statistical procedures needed to be developed before SWAP 
could be used in routine follow-up. With the recently developed SITA SWAP, its 
manufacturer has stated that the inter-test variability has been greatly reduced, 
compared to the SWAP Full Threshold strategy.15 In a cross-sectional study, Bengts-
son et al.16 recently found an equal diagnostic sensitivity of SAP and SWAP in early 
glaucoma, using three strategies (Full Threshold SWAP, SITA SWAP and SITA Fast 
SAP). A limitation of their study, however, was that none of the abnormal fields was 
confirmed by repeated testing, so it is unclear to what extent their data contained 
false positive fields in any of the three test strategies.
Taken together, it is unclear what the clinical role of SWAP is in the early detec-
tion of glaucomatous conversion in OH. Therefore, we have currently compared 
the moment of glaucomatous conversion between SWAP and SAP in a long-term 
follow-up study of OH.
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MeThods
Participants
Four hundred and sixteen (416) subjects with an elevated intra-ocular pressure 
(IOP), recruited consecutively between November 1997 and March 2001, were 
tested with both SAP and SWAP. They were tested once every 6 months during 
seven to ten years or until the onset of conversion (study endpoint). At study entry, 
all participants had an IOP ≥22 mmHg and ≤32 mmHg by Goldmann applanation 
tonometry in both eyes and normal visual fields with SAP on at least two separate 
occasions. The SAP fields were undertaken either prior to the study in standard 
clinical care, or else within the study, in which case the participants had to undergo 
2 SAP fields within one month. The second SAP was used as baseline measure-
ment for further analysis. All visual fields were undertaken by trained, experienced 
technicians. A normal visual field by SAP was defined as a glaucoma hemifield test 
of ‘Within normal limits’ and no abnormalities in the total and/or pattern deviation 
probability plots. During inclusion, all participants were labelled as high or low 
risk for converting to glaucoma. To that end, we took images with the GDx-Nerve 
Fiber Analyzer (GDx-NFA) (Laser Diagnostic Technologies, Dublin, CA, USA) of 
each eye and compared it to our own normative database. If an individual’s data 
fell below the 2nd percentile, he/she was considered as high risk, otherwise as low 
risk. None of the participants were stratified for other variables, including central 
corneal thickness and intraocular pressure. All included participants were of white 
ethnic origin, had a best corrected Snellen visual acuity of at least 20/40 in both 
eyes, and had an unremarkable slit lamp examination, including open angles on 
gonioscopy. The appearance of the optic disc was not a selection criterion. Sub-
jects were excluded from participation in the presence of any significant coexisting 
ocular or systemic diseases known to possibly affect the visual field (e.g. diabetes 
mellitus), a family history of glaucoma, a history of intraocular surgery (except for 
uncomplicated cataract surgery), uncontrollable arterial hypertension, or any previ-
ous use of IOP-lowering agents within 3 months before the measurements.
Participants took part in a double masked placebo-controlled study on the 
effect of beta-blockers on the development of glaucomatous retinal nerve fiber 
layer defects and visual field loss in elevated IOP. In this 3-arm study, participants 
were randomly allocated to either Betaxolol, Timolol (Alcon Laboratories, Inc., Fort 
Worth, TX, USA) or placebo eyedrops. In the same session as the perimetric testing 
mentioned in this report, participants were tested every 6 months by several im-
aging techniques, including scanning laser polarimetry (GDx, Carl Zeiss Meditec, 
Inc., Dublin, CA, USA), scanning laser tomography (Heidelberg Retina Tomograph 
(HRT), Heidelberg Engineering GmbH, Dossenheim, Germany) and simultaneous 
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stereoscopic photos of the optic disc. The results of these structural measurements 
are beyond the scope of the current paper.
The methods and procedures used in this study adhered to the Declaration 
of Helsinki. Informed consent was obtained from all participants. This study was 
approved by the Medical Ethics Committee of the Erasmus Medical Centre, Rot-
terdam, The Netherlands.
Test strategies
SAP and SWAP were measured with the Humphrey Field Analyzer II [HFA] (Carl 
Zeiss Meditec, Dublin, CA, USA) by means of the 24-2 Full Threshold test para-
digm. To save test-time, we decided to use SITA Standard in SAP instead of the 
Full Threshold strategy, as soon as SITA Standard became available. Whenever 
defects appeared upon SITA Standard testing, the visual field test was repeated 
with the Full Threshold strategy to confirm any abnormal fields. In SAP, we used a 
Goldmann size III white stimulus on a white background, and in SWAP a Goldmann 
size V blue stimulus on a yellow background. All participants were allowed to adapt 
to the background light for at least 5 minutes before testing. Each participant was 
given the same instructions for the examination, regardless of their perimetric 
experience, in order to minimize the effects of operator bias. The order of mea-
surements was, per protocol, SAP OD, SAP OS, followed by SWAP OD and SWAP 
OS. Resting periods of 2 to 3 minutes were given prior to each examination and 
at 5 to 7 minutes intervals during the examination of each eye. An appropriate 
refractive correction was used for the viewing distance of the perimeter and the 
participants’ age. Visual field tests for SWAP were not corrected for any possible 
lens transmission losses. All visual fields done by the Full Threshold strategy that 
were used for analysis satisfied the following reliability criteria: fixation losses ≤20% 
and false-positive and false-negative responses ≤33%. In case of the use of the 
SITA Standard strategy, all visual fields satisfied the following, arbitrary, reliabil-
ity criteria: fixation losses ≤10%, and false-positive and false-negative responses 
≤6%. None of the visual fields showed a ‘Generalized depression of sensitivity’ on 
the Glaucoma Hemifield Test (GHT). Whether a test was classified as abnormal, 
depended on the number and probability level of abnormal points on either the 
total or pattern deviation plots, whichever showed the fewest abnormal points. 
All abnormalities had to be confirmed on a subsequent test within one year, to 
be classified as abnormal. Conversion to glaucoma was defined as a reproducible 
defect in SAP of either 1 individual point below the 0.5% probability-level, or 2 
clustered points below the 1% probability-level, or 3 clustered points below the 2% 
probability-level, or 4 clustered points below the 5% probability-level on either the 
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total deviation or the pattern deviation probability plot. We used the same criteria 
for conversion in SWAP.
Analysis
The values of the total and pattern deviation probability plot and the GHT were 
derived from the standard HFA STATPAC print-out. The definitions were analysed 
with custom-made algorithms in Microsoft Access 2000 (Microsoft Corporation, 
Redmond, WA, USA).
resulTs
Of the 416 included participants, 21 showed conversion in SAP, of whom 3 showed 
conversion in both eyes. The mean follow-up time of all participants was 7.1 [SD 
3.4] years. Of the 21 converting participants, the mean age (at the moment of 
conversion) was 65.5 [SD 9.4] years. Eleven of the 21 participants (52.4%) were men. 
The mean age of the men was 61.6 [SD 10.9] years and 69.0 [SD 6.6] years in the 
women. Seven of the 24 eyes were right ones. The mean IOP in the converted eyes 
was 29.3 mmHg [SD 3.0]. Of the 416 included participants, 64 (15.4%) were labelled 
as high risk for converting to glaucoma. Of the 21 converting participants, 7 (33.3%) 
had been labelled as high risk.
Of the 24 eyes that converted in SAP, 22 (92%) failed to show earlier conversion 
in SWAP. In fact, SAP showed earlier conversion than SWAP in 15 of these 22 eyes 
(63%). Of the entire group, only 2 eyes (8%) showed earlier SWAP conversion than 
SAP conversion by up to 18 months. SAP and SWAP showed defects at the same 
time in 3 cases (13%). In 4 other cases (17%), when SAP showed the first defects, 
SWAP data turned out to be unavailable at that specific moment, which indicates 
either earlier SAP conversion or simultaneous conversion in the two tests. In 8 of the 
832 eyes (416 participants), SWAP showed reproducible defects before completion 
of the study. In 6 of these 8 eyes (8 participants), SAP remained normal throughout 
the study. The other 2 eyes converted on SAP within the follow-up time.
The results of one participant have been presented in the figure, showing the 
absence of SWAP-defects prior to those in SAP, representing at least 63% of all 
conversions in this study.
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Figure Probability plots of visual fields in SAP and SWAP of a participant, presented for 5 consecu-
tive years. Note the appearance of visual field defects in SAP prior to SWAP, representing 63% of 
the conversions in the present study. The second visual field of 2002 is missing. All visual fields were 
performed with the Full Threshold strategy. The visual fields of the fellow eye did not show any signs 
of conversion. The participant underwent cataract surgery prior to the last 3 visual fields. Abbrevia-
tions: SAP: standard automated perimetry; SWAP: short-wavelength automated perimetry
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dIsCussIon
During long-term prospective follow-up of our large group of OH subjects (>800 
eyes), the large majority of converting eyes did not show earlier reproducible peri-
metric conversion in SWAP than in SAP. In fact, conversion occurred more often in 
SAP before it occurred in SWAP. In a small minority of converted eyes did SWAP 
defects occur prior to those in SAP, which contrasts markedly with other studies 
that suggested that SWAP defects typically precede the onset of glaucomatous 
SAP defects.7;8;10;11 All these studies used different methods of SWAP, varying in, 
amongst others, equipment and normative database. Different study-outcomes 
might therefore be expected. Some methodological differences will now be dis-
cussed in greater detail.
The criteria used for a glaucomatous visual field defect in SWAP varied across 
studies. Reus et al.17 showed that the prevalence of abnormal SWAP defects 
strongly depends on the applied criteria and that it is unclear which criteria are clini-
cally most significant. For simplicity, we have currently applied the same criteria for 
conversion in SWAP as in SAP, as was done in other studies.7;10;11 Another criterion 
we applied, was the reproducibility of any defects in both SAP and SWAP. Johnson 
et al.8 did not specify whether visual field defects were reproducible. Therefore, 
their results may in principle have contained a relatively high false positive rate. 
However, it has been shown that the reproducibility of early visual field defects 
is higher in SWAP than in SAP.7 Therefore, it remains unclear why Johnson et al.8 
found such a high incidence in abnormal SWAP visual fields compared to our study.
One limitation of our study may be that, several years into the study, we changed 
from the Full Threshold strategy to SITA Standard in SAP, in order to save test-time. 
We think this change will not have significantly altered our results, because both 
tests have been shown to yield similar outcomes.18;19 Importantly, we repeated the 
Full Threshold strategy to confirm any abnormal SITA Standard fields.
The number of subjects with OH that converted to glaucoma in our study was per-
haps smaller (5.8% in 7 to 10 years) than expected. However, this rate is somewhat 
comparable to the one in the OHTS trial.4 The OHTS trial resulted in a conversion-
rate of 4.4% in the group that was treated with hypotensive medication, and 10.9% 
in the untreated group in 5 years.4 The majority of our participants was treated 
topically with either Betaxolol or Timolol and the rest took placebo eye drops. The 
use of these beta-blockers might have been protective in our patients. In addition, 
we only used perimetric conversion as a criterion, whereas in the OHTS trial, disc 
changes were also classified as conversion. It is therefore likely that we would have 
had a higher conversion rate if we had included disc changes as conversion.
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We did not determine our own normative database for SWAP, as was done in 
previous studies.7;8;10;11 Since we used the built-in normative database, systematic 
differences between the normative database and our study group might have oc-
curred, potentially yielding an underestimated number of abnormal SWAP fields 
in our study. On the other hand, we think that most clinicians would only consider 
using SWAP on a regular basis for earlier glaucoma detection, if they could rely on 
the built-in normative database. Our current study shows that SWAP would then 
probably not be useful for early conversion detection.
A potential limitation of our present study is that we did not correct for possible 
losses of lens transmission, as was done before.7;8;10;11 Losses in lens transmission 
due to cataract cause a generalized depression of sensitivity in SWAP, but also in 
SAP.20 Arguably, any localized SWAP defects would have been deepened by cata-
ract, notably in the total deviation plot, thereby probably artifactually selectively 
increasing the SWAP conversion rate in our study more so than in SAP. Because this 
conversion rate was so low compared to that in SAP, we think that correcting for 
lens opacities would not have supported further use of SWAP for early detection of 
glaucomatous visual field defects. If clinicians were required to always correct their 
SWAP data for lens opacities, instead of using the built-in normative database as 
a straight-forward reference, we think that the role of SWAP for early detection of 
glaucoma would, again, be a priori very limited. The development of the SITA SWAP 
strategy may have improved the applicability of SWAP, for the renewed normative 
database allegedly corrects for cataractous changes.15 We think this should be 
further explored, because Sample et al. showed that the sensitivity and specificity 
for detecting glaucomatous visual field loss was virtually unaffected by correcting 
for losses of lens transmission.20 Our current study was initiated many years before 
SITA SWAP was released. We were therefore unable to test the newer version with 
its newly developed normative database. If our conclusions were largely due to the 
SWAP normative database that we used, the SITA SWAP strategy with its renewed 
normative database, might still be of use for earlier detection. This needs to be 
explored in future studies. However, since Bengtsson et al.16 found no significant 
difference in diagnostic sensitivity for early glaucoma detection between SITA 
SWAP and Full Threshold SWAP, we do not expect any substantial improvement in 
detecting early conversion of SITA SWAP over Full Threshold SWAP.
Although the design of the study by Johnson et al.8 was comparable to ours, 
we had completely different outcomes. A possible explanation of this could be 
that the outcome in Johnson’s study8 (SWAP showing defects prior to SAP) is most 
likely attributable to chance selection of subjects that had developed a selective 
damage of specific subsystems. Perhaps such selective damage only occurs in a 
small subset of patients with OH. We therefore think that early glaucomatous dam-
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age is idiosyncratic, and may become fi rst apparent in one of different pathways, 
sometimes appearing fi rst in SWAP and sometimes fi rst in SAP. Others have shown 
that, with prolonged testing, the incidence-rates of visual fi eld defects turn out to 
be similar for SWAP and SAP, suggesting that both tests detect the same disease 
(glaucoma).7 No single test could then become the gold standard in detecting 
early glaucoma. Despite its limitations, SAP has become a standard in clinical care 
across the world. SWAP, however, has never gained such widespread acceptance, 
for various reasons, some of which have been discussed earlier. It is possible that 
SITA SWAP will turn out to be useful for early detection of glaucomatous conversion. 
To date, there is insuffi cient evidence for that. We therefore recommend clinicians 
to use SAP rather than SWAP in their daily practices to detect early glaucomatous 
conversion in ocular hypertension.
Although early SWAP visual fi eld defects have been suggested to typically pre-
cede those in SAP in conversion from OH to POAG, our prospective, longitudinal 
follow-up study does not support this suggestion. On the contrary, SAP appears to 
be at least as sensitive to conversion as SWAP in a large majority of eyes.
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absTraCT
Purpose. To explore the rate of conversion from ocular hypertension to glaucoma 
by progression analyses on visual fields and scanning laser polarimetry.
Design. Longitudinal retrospective study
Participants. Four hundred sixteen subjects with ocular hypertension (intraocular 
pressure (IOP) ≥22 and ≤32 mmHg and normal visual fields)
Methods. Subjects were measured every 6 months with a Humphrey Field Analyzer 
(HFA, 24-2 program; Carl Zeiss Meditec (CZM), Dublin, USA) and with scanning 
laser polarimetry (GDxVCC and GDxECC; CZM). Conversion to glaucoma was 
defined as a flagging by the commercially available progression software (Guided 
/ Glaucoma Progression Analysis (GPA); HFA-II-i, Software Version 4.2, CZM; GDx 
Review with GPA; Software Version 6.0.1, CZM) as ‘likely progression’ or, in case 
of HFA, a negative rate of progression that was statistically significant, or in case 
of GDxVCC, a nerve fiber indicator (NFI) > 35 on at least 3 consecutive measure-
ments. Two hundred and thirty-eight eyes of 134 subjects could be used for the 
progression analyses.
Main outcome measures. Number of eyes converting to glaucoma.
Results. 61 of the 238 eyes converted to glaucoma. 35 eyes were flagged by 
GDxECC, 36 by GDxVCC and 12 by standard automated perimetry (SAP). Only 3 
converting eyes were flagged by all 3 techniques.
Conclusions. SLP flags conversion to glaucoma earlier than SAP in the large major-
ity of cases, potentially leading to earlier treatment preventing further progression 
to moderate or severe glaucoma. However, because of little overlap in flagging 
conversion, we recommend the use of commercially available progression analyses 
of both structural and functional measurements to detect conversion to glaucoma.
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InTroduCTIon
The Rotterdam Ocular Hypertension Trial (ROHT) is a randomised controlled trial 
into preventing ocular hypertension (OH) to convert into glaucoma. It is a double 
masked placebo-controlled study on the effect of beta-blockers on the develop-
ment of glaucomatous retinal nerve fiber layer defects and visual field loss in eyes 
with elevated IOP. In this 3-arm study, patients were randomly allocated to either 
Betaxolol, Timolol (Alcon Laboratories, Inc., Fort Worth, TX, USA) or placebo eye 
drops. To be able to conclude whether topical beta-blockers protect patients with 
OH to convert to glaucoma, one needs to define conversion to glaucoma. In previ-
ous studies on preventing or delaying glaucoma in eyes with OH, conversion to 
glaucoma was usually based on changes in visual field or in the appearance of the 
optic disc, scored by reading centres.1;2 In daily practice, changes in function or 
structure are increasingly based on the outcome of measurements of perimetry 
and imaging devices, such as scanning laser polarimetry (SLP) and optical coher-
ence tomography. In the current study, we explored the incidence of conversion to 
glaucoma according to the current commercially available progression analyses on 
standard automated perimetry (SAP) and SLP. The results of the capability of beta-
blockers to prevent OH converting to glaucoma, will be reported on in chapter 4.
MeThods
Patients
Four hundred and nine subjects with an elevated intra-ocular pressure (IOP), re-
cruited consecutively between November 1997 and March 2001, were followed up 
with perimetry and scanning laser polarimetry. They were tested once every half 
year during seven to ten years or until the onset of conversion (study endpoint). 
At study entry, all patients had an IOP ≥22 mmHg and ≤32 mmHg by Goldmann 
applanation tonometry in both eyes and normal visual fields with SAP on at least 
two separate occasions. A normal visual field by SAP was defined as a glaucoma 
hemifield test of ‘Within normal limits’ and no nerve fiber bundle abnormalities, as 
described by Keltner et al3, in the total and/or pattern deviation probability plots. 
All included patients were of white ethnic origin, had a corrected distance Snellen 
visual acuity of at least 20/40 in both eyes, and had an unremarkable slit lamp 
examination, including open angles on gonioscopy. The appearance of the optic 
disc was not a selection criterion. Our study endpoint, conversion to glaucoma, 
was defined as a reproducible appearance in SAP of either 1 individual point below 
the 0.5% probability-level, or 2 clustered points below the 1% probability-level, or 3 
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clustered points below the 2% probability-level, or 4 clustered points below the 5% 
probability-level on either the total deviation or the pattern deviation probability 
plot. These criteria have been used and described before4, not only for SAP, but 
also for short wavelength automated perimetry (SWAP). Patients were excluded 
from participation in the presence of any significant coexisting ocular or systemic 
diseases known to possibly affect the visual field (e.g. diabetes mellitus), a family 
history of glaucoma, a history of intraocular surgery (except for uncomplicated 
cataract surgery), uncontrollable arterial hypertension, or any previous use of IOP-
lowering agents within 3 months before the measurements.
Patients took part in a double masked placebo-controlled study on the effect 
of beta-blockers on the development of glaucomatous retinal nerve fiber layer 
defects and visual field loss in elevated IOP. In this 3-arm study, patients were 
randomly allocated to Betaxolol, Timolol (Alcon Laboratories, Inc., Fort Worth, TX, 
USA) or placebo eye drops. The effects of the two beta-blockers on the conversion 
rate to glaucoma will be described in chapter 4.
The methods and procedures used in this study adhered to the Declaration 
of Helsinki. Informed consent was obtained from all participants. This study was 
approved by the Medical Ethics Committee of the Erasmus Medical Centre, Rot-
terdam, The Netherlands and registered in the Dutch Trial Register.
Test strategies
SAP was measured with the Humphrey Field Analyzer II [HFA] (Carl Zeiss Meditec 
(CZM), Dublin, CA, USA) by means of the 24-2 Full Threshold (FT) test paradigm. 
To save test-time, we decided to use SITA Standard instead of the FT strategy, 
after SITA Standard (SS) became available. Whenever any defects appeared upon 
SITA Standard testing, the visual field test was repeated with the FT strategy to 
confirm any abnormal fields. When no defects were present with the FT strategy, 
the testing was prolonged with FT measurements only. SAP test strategies and 
criteria have been described in detail before4.
SLP was measured with the GDx (CZM, Dublin, CA, USA), with both the variable 
corneal compensation (GDxVCC) and enhanced corneal compensation (GDxECC). 
For each subject, anterior segment birefringence was assessed, after which images 
were obtained with both VCC and ECC. All accepted scans were of high quality, i.e. 
with a centred optic disc, well-focused, evenly and justly illuminated throughout 
the image, and without any motion artefacts.
Progression analyses
For both SAP and SLP, Carl Zeiss Meditec developed progression software, the 
Guided (SAP) / Glaucoma (SLP) Progression Analysis (GPA). In SAP, this software 
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is incorporated in the HFA (HFA-II-i, Software Version 4.2, CZM, Dublin, CA, USA). 
The GPA parameters indicating progression result from a trend analysis, i.e. the 
rate of progression and its significance. This linear regression analysis is based 
on the visual field index (VFI). We considered an eye as converting to glaucoma 
in case of a negative rate of change that was statistically significant. The GPA 
progression analysis also includes an event analysis, in which the individual test 
locations of the deviation plots of each follow up measurement are compared with 
the baseline measurements. The result is ‘no progression’, if there is no change, 
‘possible progression’ if change is detected in only one visit, or ‘likely progression’ 
if this loss is confirmed in a subsequent measurement. In case of event analysis, 
we considered an eye as converting to glaucoma if a follow up measurement was 
flagged as ‘likely progressing’. For SAP, the progression analysis was based on 
the SS-strategy. The GPA software allowed us to include measurements performed 
with the FT-strategy, but only when baseline measurements were obtained through 
the same FT-strategy.
In case of SLP, we used GPA software that was for investigational use only (GDx 
Review with GPA; Software Version 6.0.1, CZM, Dublin, CA, USA). This software is 
comparable with the GPA software commercially available on the current GDxPRO, 
the successor to the GDxVCC. The parameters derived from the progression 
analysis include RNFL image change (Image Progression Map (IPM)), TSNIT change 
(TSNIT Progression Graph (TPG)), and change in summary parameters (SP) (TSNI-
TAverage, SuperiorAverage, InferiorAverage). We considered an eye as converting 
to glaucoma in case of at least one out of the 3 parameters (IPM, TPG, SP) being 
flagged as likely progression. We also used the NFI change for detecting conver-
sion. The nerve fiber indicator (NFI) is a clinically important parameter, ranging 
from 1 to 99. It has been trained to increase with the likelihood of glaucoma and 
it has been reported to have the best diagnostic accuracy among the 6 standard 
parameters.5 We defined conversion based on NFI at a value ≥ 35, confirmed on 
at least 2 consecutive occasions. In case of an NFI ≥ 35 at baseline, an increase 
of >30%, confirmed on at least 2 consecutive occasions, was also considered as 
progression. Our GPA software only calculated the NFI in GDxVCC data and not in 
GDxECC data. Therefore, we are able to only present the NFI-analyses of GDxVCC.
The selection of data for progression analyses in the current study, was based on 
the presence of GDxECC measurements, because GDxECC was incorporated into 
the study last, in 2004. During follow up of the participants, more measurements 
were collected than fit into the progression analyses. The GPA of the GDx oper-
ates with a maximum of 8 measurements. We therefore selected the first 3 visits in 
which GDxECC was performed, as well as the last 3 visits. Two additional visits were 
selected from the visits in between the first and last 3 visits, based on equal division 
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of the measurements over time. The dates of the SAP measurements that we used 
for the progression analyses matched those of the GDx measurements.
Data Analysis
The paired T-test was used to test for any differences between parameters at study 
onset and endpoint. The unpaired T-test was used to test for differences between 
eyes showing conversion and those not showing conversion. In the current study, 
a significance level of 0.05 was considered to be statistically significant. We con-
structed a Venn diagram to present all combinations between the converted eyes 
flagged by SAP, GDxECC and GDxVCC. The definitions were analysed with custom-
made algorithms in Microsoft Access 2003 (Microsoft Corporation, Redmond, WA, 
USA) + SPSS Statistics 22 for Windows (release 22.0.0, 2013, IBM SPSS Statistics, 
New York, USA).
Of the 818 eyes of the 409 eligible subjects, 580 eyes were excluded from analysis 
for the following reasons: a cholesterol crystal that was present in a retinal artery 
causing a visual field defect (1), no possibility to perform GPA on all 3 measure-
ments, i.e. GDxECC, GDxVCC and SAP, because of dropout before incorporation 
of the GDxECC, leading to the absence or too few measurements (454), or the 
measurements did not meet the software’s inclusion criteria (i.e. the intermittent 
use of SS and FT test strategies in SAP or quality control errors in the GDx GPA 
software) (125). Therefore, 134 subjects (238 eyes) with elevated IOP were analyzed 
for the present study. The baseline characteristics of all included subjects and eyes 
have been shown in Table 1. The mean follow up time was 3.8 [SD 0.8] years.
resulTs
Of the 238 included eyes, 61 eyes of 48 subjects showed conversion in one of 
the progression analyses with the 3 techniques, i.e. GDxECC, GDxVCC or SAP. Of 
these 61 converting eyes, 35 were flagged by GDxECC, 36 by GDxVCC and 12 by 
SAP. In the progression analysis of the GDxVCC, 15 of the 36 converting eyes were 
flagged as progressing by the criterion of an NFI ≥ 35, or, in case of an NFI ≥ 35 
at baseline, an increase of >30%, both criteria confirmed on at least 2 consecutive 
occasions. In the SAP progression analyses, 6 eyes were flagged as progressing by 
trend analysis and another 6 eyes by event analysis. Most progression was flagged 
by GDx (57% by GDxECC and 59% by GDxVCC). Only 3 cases were flagged by all 3 
commercially available progression analyses of GDxECC, GDxVCC and SAP. Figure 
1 shows a Venn diagram of the number of converting eyes flagged by each analysis.
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Table 1 Baseline characteristics of included subjects and eyes.
Subject Characteristics units Subjects (134)
Age years 62.4 [9.7]
Men N (%) 59 (44)
   
Eye Characteristics  Eyes (238)
CDVA NA 1.06 [0.26]
CCT µm 578.44 [32.41]
IOP mmHg 26.38 [2.81]
SAP - MD dB 0.87 [1.03]
SAP - VFI % 99.76 [0.47]
VCC - NFI NA 23.34 [10.24]
VCC – TSNIT Average µm 51.21 [5.13]
ECC – TSNIT Average µm 50.59 [4.88]
All numbers are presented as Mean [Standard Deviation]
Abbreviations: CDVA: corrected distance visual acuity [SD in Snellen letter lines]6; CCT: central cor-
neal thickness; IOP: intraocular pressure; SAP: standard automated perimetry; MD: mean deviation; 
VFI: visual field index; VCC: GDx with variable corneal compensation; NFI: nerve fiber indicator; ECC: 
GDx with enhanced corneal compensation; N: number; NA: not applicable.
Figure 1 Venn diagram representing the number of converting eyes as detected with commercially 
available progression analyses for GDxECC, GDxVCC and SAP. In case of GDxVCC, the number 
of converting eyes based on an NFI ≥ 35 is presented between brackets. In case of an NFI ≥ 35 at 
baseline, an increase of >30%, twice reproduced consecutively, was required to be considered as 
conversion.
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In the GDxVCC, a total of 36 eyes were flagged as converting to glaucoma. Of 
those eyes, only 28% (n=10) was flagged by both analyses, i.e. the progression 
flagged by the GPA software and an increase in NFI to ≥ 35, or, a reproducible 
increase of >30% in case of an NFI ≥ 35 at baseline.
Of the 48 subjects who showed conversion, 46% (n=22) were men. The mean age 
of these 48 subjects was 66.2 years (SD, 9.4). The characteristics of the non-convert-
ed eyes, as well of the converting eyes have been shown in Table 2. The baseline 
characteristics of the converting eyes and those not converting (as described in 
Table 2) were not statistically significant different in CDVA, IOP and CCT (p > 0.31), 
nor in any of the parameters produced by the 3 devices (p > 0.34).
In all 238 included eyes, both non-converting and converting, all parameters 
changed statistically significantly (p < 0.004, paired T-test) between study onset 
and endpoint, except for the MD and the GDx VCC’s TSNIT average. The latter 
changed only in the group of converting eyes. The change between study onset 
and endpoint was larger for all parameters in the converting eyes than for the 
non-converting eyes (p < 0.02), except for the IOP.
dIsCussIon
Twenty-six percent of the eyes with ocular hypertension in our data showed conver-
sion to glaucoma in approximately 4 years follow-up by the criteria we adopted, 
using the proprietary progression analysis programmes in function and structure. 
Compared to the outcome of other trials, such as the OHTS and EGPS 7;8, this is a 
large proportion of converting eyes. In the OHTS and EGPS, the rate of conversion 
was < 15% within 5 years (treated and untreated eyes). This difference is probably 
mainly due to differences in methodology and criteria used to define ocular hyper-
tension and (conversion to) glaucoma. In the OHTS and EGPS, ocular hypertension 
was defined by the intraocular pressure and the absence of visual field defects as 
well as a normal appearance of the optic disc.1;2 We included subjects based only 
on the IOP and visual field, not defining the absence of structural damage. This 
might have lead to including relatively more advanced preperimetric glaucoma-
tous eyes, potentially already having structural damage. This is further supported 
by the fact that we had several eyes at baseline with an NFI > 35, but without any 
visual field damage.
A second explanation of our relatively high rate of conversion might be the use 
of SLP in defining conversion to glaucoma. Apparently, structural damage often 
precedes functional damage in glaucomatous eyes.9;10 Our data confirm this phe-
nomenon by showing a much higher conversion rate with SLP than with SAP. Only 
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20% of the converted eyes were flagged by the progression analysis software of 
SAP, while 89% were flagged by SLP. It is unclear whether all these structural con-
versions would also have been detected by judging the appearance of the optic 
disc. Judging (conversion to) glaucoma and its progression by the appearance of 
the optic disc11-13, and also matching it with visual field progression14, has been 
shown to be difficult.
Our data show a relatively poor overlap between conversion on SAP and on SLP. 
Only 5% (3 eyes) of all converting eyes showed conversion to glaucoma in all 3 
progression analyses (SAP, GDxVCC and GDxECC). In other words, there was poor 
agreement in conversion rates between structural and functional measurements. 
This agrees well with other studies into structural and functional progression and 
conversion in ocular hypertension and glaucoma, mainly showing a poor agree-
ment between structure and function.15-20 Unfortunately, an accurate comparison 
between our current study and other studies is not possible, mainly because a) few 
studies have been presented using SLP for progression analysis, and more impor-
tantly, b) our study explicitly investigated the conversion of ocular hypertension to 
glaucoma, a transition without any gold standard, which hampers the comparison 
with other trials.
The baseline characteristics of our subjects were solid, illustrated by the absence 
of any statistically significant differences between the converting and non-convert-
ing eyes. The small change over time in the parameters of the non-converting eyes 
might be due to natural aging. A similar effect of age on RNFL thickness in SLP has 
been reported earlier.21;22 The relatively small decrease over time in VFI and MD 
within the converting eyes might be due to the ceiling effect, described by Artes 
et al.23 Apparently, when no or very little visual field damage exists, changes in VFI 
are much harder to detect than changes in glaucomatous visual field damage with 
an MD <-5dB. The VFI therefore appears to be quite insensitive to early changes 
in glaucomatous damage.
A methodological limitation of our study was the development of devices dur-
ing the course of the trial. In SAP, we decided to use the SITA-Standard (SS) test 
paradigm instead of the Full-Threshold (FT) test paradigm, since it was thought 
to improve the quality and time of the visual fields, without compromising their 
outcome.24-26 Unfortunately, the GPA, which was developed later, is not capable of 
fully combining FT and SS strategies. This lead to the exclusion of many eyes in 
our analyses. SLP was introduced in the current trial since its beginning by the pre-
decessors of the GDxECC (Nerve Fiber Analyzer, Laser Diagnostics Technologies, 
San Diego, CA, USA). Because these earlier devices are currently no longer used, 
we chose to implement the measurements of GDxECC and VCC in the current 
analyses since they became available in 2004. Unfortunately, this has inevitably lead 
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to a signifi cant decrease in follow-up time. These changes over time of the com-
mercially available devices in our trial is a refl ection of an ophthalmologist’s daily 
practice. The development of devices over the years shows a great improvement in 
sensitivity of diagnosing glaucoma, but complicates progression analyses, largely 
because the newer versions are poorly, or not at all, backwards compatible.
The progression analysis software of both SAP and SLP incorporates trend as 
well as event analysis. Event analysis may be more sensitive in detecting glaucoma 
progression than trend analysis27;28, especially in a relatively short period of time. 
Combining both analyses is desirable in diagnosing conversion to glaucoma.29 In 
the analysis of our SLP data, we therefore incorporated the NFI as an extra event 
analysis. This intuitive parameter probably refl ects the use of SLP in daily care. The 
NFI was developed as a classifi er. It therefore refl ects the likelihood of glaucoma 
but not the severity of the disease. It has been shown to be quite accurate in dis-
criminating between normal and glaucomatous eyes.30;31 Obviously the likelihood 
of glaucoma may go up with more advanced disease, but one should be aware 
that the NFI was never developed for monitoring glaucoma. The criterion of a 
change in NFI from below 35 to above 35 that we used had to do with a change in 
classifi cation (normal versus glaucomatous). The other NFI criterion that we used (a 
change of >30% in case of a high NFI at baseline) therefore made less sense, and it 
turned out to be indeed quite insensitive, albeit more sensitive than SAP.
In our study, SLP fl agged conversion to glaucoma earlier than SAP in the large 
majority of cases, potentially leading to earlier treatment preventing further pro-
gression to moderate or severe glaucoma. Based on the outcome of our study, 
we advise to use SLP, or another device measuring structural change in glaucoma, 
in daily practice to intercept conversion to glaucoma, when possible combined 
with SAP. SAP alone turned out to be relatively insensitive to detect conversion 
to glaucoma; this applied to the NFI alone as well. We recommend the use of 
commercially available progression software of both structural and functional 
measurements to detect conversion to glaucoma.
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absTraCT
Purpose. To explore the effect of topical beta-blockers on the rate of conversion of 
ocular hypertension to glaucoma.
Design. Randomized placebo-controlled study
Participants. Four hundred sixteen subjects with ocular hypertension (intraocular 
pressure (IOP) ≥22 and ≤32 mmHg and normal visual fields)
Methods. Subjects were randomly allocated to either Betaxolol 0.25%, Timolol 
0.25% or placebo eyedrops. Every 6 months the intraocular pressure was deter-
mined, as well as the visual field (Standard Automated Perimetry (SAP); Carl Zeiss 
Meditec (CZM), Dublin, USA) and scanning laser polarimetry (SLP; GDxVCC and 
GDxECC; CZM) was also performed. Conversion to glaucoma was defined by com-
mercially available progression software (Guided / Glaucoma Progression Analysis 
(GPA); HFA-II-i, Software Version 4.2, CZM; GDx Review with GPA; Software Version 
6.0.1, CZM) software of all 3 techniques. Two hundred and thirty eight eyes of 134 
subjects could be used for the progression analyses.
Main outcome measures. Number of eyes converting to glaucoma and IOP for 
eyes using Betaxolol, Timolol and placebo eyedrops.
Results. 61 of the 238 eyes converted to glaucoma, of which 16 within the Timolol-
group, 21 within the Betaxolol-group and 24 eyes that were treated with placebo 
eyedrops. The IOP decreased statistically significantly (p < 0.05) by 18% in eyes 
receiving Timolol, 12% in eyes receiving Betaxolol and 8% in eyes receiving pla-
cebo eyedrops.
Conclusions. In this study, we presented that beta-blockers show no advantage in 
preventing ocular hypertension to convert to glaucoma, as compared to placebo.
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InTroduCTIon
Whether Ocular Hypertension (OH) should be medically treated to prevent the 
conversion to glaucoma is subject to debate. Several large studies have presented 
conflicting results whether or not to treat ocular hypertension. The Ocular Hyper-
tension Treatment Study (OHTS) showed an approximately 50% reduction of the 
risk of developing glaucoma by topical medication.1 The European Glaucoma 
Prevention Study (EGPS) showed no advantage of dorzolamide against placebo in 
preventing or delaying the onset of glaucoma.2 The current study, The Rotterdam 
Ocular Hypertension Trial (ROHT), is a randomised controlled trial into prevent-
ing OH from converting to glaucoma. It is a double masked placebo-controlled 
study on the effect of beta-blockers (Betaxolol, Timolol (Alcon Laboratories, Inc., 
Fort Worth, TX, USA)) on the development of glaucomatous retinal nerve fibre 
layer defects and visual field loss in eyes with elevated IOP. Currently, the use of 
progression analyses software on diagnostic tools, such as for standard automated 
perimetry (SAP) and sophisticated imaging of the eye, have entered the daily care 
for glaucoma patients. In the current study, we have used these commercially avail-
able progression analysis software packages to detect conversion from OH to glau-
coma, both for SAP and for Scanning Laser Polarimetry (SLP). More importantly, we 
explored the effect of beta-blockers on the conversion rates.
MeThods
Four hundred and sixteen (416) subjects with an elevated intra-ocular pressure 
(IOP), were included in our randomised placebo-controlled study. In this 3-arm 
study, patients were randomly allocated to either Betaxolol 0.25%, Timolol 0.25% 
(Alcon Laboratories, Inc., Fort Worth, TX, USA) or placebo eyedrops. The IOP was 
measured every 6 months and subjects were also tested with both SAP (Humphrey 
Field Analyzer II [HFA] (Carl Zeiss Meditec (CZM), Dublin, CA, USA) and SLP (GDx 
(CZM, Dublin, CA, USA)). SAP was measured by means of the 24-2 Full Threshold 
(FT) test paradigm. To save test-time, we decided to use SITA Standard instead of 
the FT strategy, after SITA Standard (SS) became available. SLP was measured with 
the GDx with both the variable corneal compensation (GDxVCC) and enhanced 
corneal compensation (GDxECC). For each subject, anterior segment birefrin-
gence was assessed, after which images were obtained with both VCC and ECC. 
Next to the SAP and SLP testing mentioned in this report, patients were tested 
every 6 months by several other techniques as well, including Short Wavelength 
Automated Perimetry (SWAP, CZM, Inc., Dublin, CA, USA), scanning laser tomog-
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raphy (Heidelberg Retina Tomograph (HRT), Heidelberg Engineering GmbH, 
Dossenheim, Germany) and simultaneous stereoscopic photos of the optic disc. 
At study entry, all patients had an IOP ≥22 mmHg and ≤32 mmHg by Goldmann 
applanation tonometry in both eyes and normal visual fields with SAP on at least 
two separate occasions. A normal visual field by SAP was defined as a glaucoma 
hemifield test of ‘Within normal limits’ and no nerve fibre bundle abnormalities, as 
described by Keltner et al3, in the total and/or pattern deviation probability plots. 
The appearance of the optic disc was not a selection criterion. Detailed inclusion 
criteria and testing strategies have been described before.4;5
We retrospectively analysed the data by performing progression analyses on 
the SAP and SLP data by using the commercially available software developed by 
CZM. For SAP, the Guided Progression Analysis (GPA) is incorporated in the HFA 
(HFA-II-i, Software Version 4.2, CZM, Dublin, CA, USA). In case of SLP, we used 
GPA software that was for investigational use only (GDx Review with GPA; Software 
Version 6.0.1, CZM, Dublin, CA, USA). The parameters and criteria used for this 
progression analysis and conversion to glaucoma have been described before.5 
We compared the IOP and the incidence of conversion flagged by the software 
analyses between the subjects using Betaxolol, Timolol and placebo eyedrops.
Of the 818 eyes of the 409 eligible subjects, 580 eyes were excluded from analysis 
for the following reasons: a cholesterol crystal that was present in a retinal artery 
causing a visual field defect (1), no possibility to perform GPA on all 3 measure-
ments, i.e. GDxECC, GDxVCC and SAP, because of dropout before incorporation 
of the GDxECC, leading to the absence or too few measurements (454), or the 
measurements did not meet the software’s inclusion criteria (i.e. the intermittent 
use of SS and FT test strategies in SAP or quality control errors in the GDx GPA 
software) (125). Therefore, 134 subjects (238 eyes) with elevated IOP were analyzed 
for the present study.
resulTs
Of the 238 included eyes, 61 eyes showed progression in one of the progression 
analyses with the 3 techniques, i.e. GDxECC, GDxVCC and SAP. The mean age of 
all 134 participants (at study endpoint) was 62.4 years (SD, 9.7), of whom 44% (n=59) 
were men. The mean follow up time was 3.8 [SD 0.8] years. The characteristics of all 
included eyes per treatment group have been presented in Table 1.
A total of 61 eyes (26%) converted to glaucoma, of which 16 (21%) within the 
Timolol-group, 21 (29%) within the Betaxolol-group and 24 (27%) eyes that were 
treated with placebo eyedrops. The incidence of conversion between these 3 
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groups did not statistically significantly differ from each other (Chi-square test, p = 
0.52). Of the 48 subjects that showed progression, 46% (n=22) were men. The mean 
age of these 62 subjects was 66.2 years (SD, 9.4). Table 2 shows the characteristics 
of the converted eyes for each treatment group.
The intraocular pressure (IOP) decreased statistically significantly in all three 
groups (paired T-test, p < 0.05 for Betaxolol, Timolol and placebo). The eyes using 
Table 1 Characteristics per treatment group
 
Subjects
 
n
Timolol 0.25% Betaxolol 0.25% Placebo
42 41 51
Age yrs 62.09 [9.70] 64.98 [10.56] 60.64 [8.61]
Gender 
(male)
n 20 17 22
Eyes n 76 73 89
BCVA  1.10 [0.32] 1.06 [0.28] 1.03 [0.17]
CCT µm 577.18 [36.12] 577.59 [34.64] 580.20 [27.00]
  START END START END START END
IOP mmHg 26.20 [2.79] 21.22 [3.31] 26.97 [2.44] 23.53 [2.87] 26.04 [3.07] 23.66 [3.08]
SAP - MD dB 0.82 [0.93] 0.82 [0.98] 0.97 [1.20] 0.79 [1.26] 0.82 [0.96] 0.81 [1.02]
SAP - VFI dB 99.76 [0.54] 99.55 [0.74] 99.79 [0.41] 99.51 [0.77] 99.72 [0.45] 99.61 [0.60]
VCC - NFI NA 24.83 [10.71] 28.05 [13.23] 22.36 [10.49] 26.86 [13.94] 22.89 [9.58] 25.40 [12.54]
Abbreviations: BCVA = best corrected visual acuity; CCT = central corneal thickness; IOP = intraocu-
lar pressure; SAP = standard automated perimetry; MD = mean deviation; VFI = visual field index; dB 
= decibel; VCC = scanning laser polarimetry with variable corneal compensation; NFI = nerve fiber 
indicator; NA = not applicable.
All parameters presented as number (n) or mean [standard deviation].
Table 2 Characteristics for all converted eyes per group
Subjects N (%)
Timolol 0.25% Betaxolol 0.25% Placebo
13 (31) 18 (44) 17 (33)
Eyes N (%) 16 (21) 21 (29) 24 (27)
  BASELINE END BASELINE END BASELINE END
IOP mmHg 26.00 [2.37] 20.37 [3.26] 27.14 [2.20] 23.81 [3.30] 26.83 [2.51] 25.33 [2.70]
SAP - MD dB 0.68 [0.97] 0.48 [1.11] 0.97 [1.22] 0.60 [1.46] 0.78 [0.90] 0.67 [1.09]
SAP - VFI dB 99.75 [0.77] 99.00 [1.03] 99.86 [0.36] 99.57 [0.51] 99.63 [0.49] 99.42 [0.65]
VCC - NFI  24.88 [8.53] 34.56 [15.68] 22.33 [10.69] 32.76 [15.86] 24.96 [10.56] 32.63 [17.05]
Abbreviations: N (%) = number (percentage of included eyes within group); IOP = intraocular pres-
sure; SAP = standard automated perimetry; MD = mean deviation; VFI = visual field index; dB = 
decibel; VCC = scanning laser polarimetry with variable corneal compensation; NFI = nerve fiber 
indicator; NA = not applicable.
All parameters presented as number (n) or mean [standard deviation].
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Timolol eyedrops showed the largest decrease in IOP by 18%. The IOP in eyes us-
ing Betaxolol and placebo eyedrops decreased by 12% and 8%, respectively. This 
difference in decrease in IOP between these 3 groups was statistically signifi cant 
(Generalised Estimating Equations, p < 0.05). Figure 1 presents a graph with the 
IOP at baseline and endpoint for all three medication groups. Figure 2 presents a 
histogram of the decrease in IOP for converted and not converted eyes.
EndBaseline
In
tr
ao
cu
la
r 
pr
es
su
re
28
26
24
22
20
Timolol 0.25%
Placebo
Betaxolol 0.25%
Medication
Page 1
Figure 1 Mean intraocular pressure at 
baseline and endpoint for all eyes includ-
ed using Betaxolol, Timolol or placebo 
eyedrops.
Figure 2 Percentage of decrease in intra-
ocular pressure (IOP) in eyes converting 
or not converting to glaucoma for each 
medication group separately.
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ConClusIon
Beta-blockers induced a significant decrease in the intraocular pressure (IOP), but 
did not significantly reduce the conversion rates in ocular hypertensive eyes to 
glaucoma, compared to placebo. Timolol gave the largest decrease in IOP (18%) 
and lead to the fewest eyes converting to glaucoma (21%). This percentage was, 
however, not statistically significantly lower than the conversion rate in eyes receiv-
ing Betaxolol or placebo eyedrops. In the two largest trials in preventing ocular 
hypertension from converting to glaucoma, the Ocular Hypertension Treatment 
Study (OHTS)1 and the European Glaucoma Prevention Study (EGPS)2, a mean 
reduction in IOP of 22% was achieved, with topical treatment, which was more 
effective in preventing conversion to glaucoma. However, according to our study, 
a higher decrease in IOP, as Timolol elicits compared to Betaxolol and placebo 
eyedrops, did not significantly reduce the chance of conversion to glaucoma.
A total of 26% of the included ocular hypertensive eyes showed conversion to 
glaucoma within 4 years. This is a much higher conversion rate than in the OHTS 
and EGPS. The OHTS showed a conversion rate in 5 years of 4.4% in eyes treated 
with topical medication and 9% in the control group, which did not receive any 
treatment. The EGPS showed a higher rate of conversion in 5 years than the OHTS; 
13.4% in eyes treated with dorzolamide and 14.1% in eyes receiving placebo 
eyedrops. This significant difference in conversion rates between the OHTS and 
the EGPS was probably induced by applying different criteria at inclusion and as 
conversion to glaucoma. We included subjects based only on the IOP and their 
visual fields, not taking the appearance of the optic disc into account, as the 
other studies did.6;7 This might have lead to including relatively more advanced 
preperimetric glaucomatous eyes, potentially already having structural damage. 
Also applying a different criterion for conversion to glaucoma, based on newly 
developed progression analyses software, might have lead to the earlier detection 
of conversion to glaucoma.
Initially, we included a large group of subjects with OH into this study. Due to the 
development of devices during the course of the trial, we were not able to analyse 
the data of all subjects. Due to test strategies changing over time and not being 
interchangeable (in case of SAP) and due to the development of newer devices 
during the study (in case of SLP), we were forced to exclude many subjects. The 
development of devices over the years shows a great improvement in sensitivity of 
diagnosing glaucoma, but complicates progression analyses, largely because the 
newer versions are poorly, or not at all, backwards compatible.
Beta-blockers are widely used in treating glaucoma. Both Timolol, a non-
selective beta-adrenergic antagonist, and Betaxolol, a beta1-selective antagonist, 
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reduce aqueous humor secretion and induce an increased retinal perfusion8;9. 
Betaxolol reaches a smaller decrease in IOP than Timolol does.10 However, due to 
its neuroprotective effect by its calcium-channel blocking properties11, Betaxolol 
was thought to have an equal or even better result in preventing glaucomatous 
progression, compared to Timolol.12-14 We therefore included both beta-blockers 
into this study to compare the effect of both eyedrops on the IOP and conversion 
of OH to glaucoma.
This study showed a higher rate of conversion to glaucoma in ocular hypertensive 
eyes treated with beta-blockers, as well as with placebo eye drops, than other trials 
have described before. We showed that, in general, beta-blockers do not prevent 
eyes with ocular hypertension from converting to glaucoma.
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absTraCT
Purpose. To determine the ability of ophthalmologists across Europe to match 
stereoscopic optic disc photographs to visual fields of varying severity.
Design. Evaluation and comparison of two diagnostic tests.
Participants. A total of 109 of 260 invited ophthalmologists in 11 European coun-
tries. These had participated in the previous European Optic Disc Assessment Trial 
(EODAT), a trial on glaucoma diagnostic accuracy based on optic discs only.
Methods. Each participant matched stereo optic disc photographs of 40 healthy 
and 48 glaucomatous eyes to a visual field, chosen from 4 options per disc. The 4 
presented visual fields included the corresponding one and 3 other visual fields, 
varying in severity. The matching accuracy and any inaccuracy per disease severity 
were calculated. Classification accuracy (as glaucomatous or healthy) was compared 
to EODAT data. Duplicate slides allowed assessing intraobserver agreement.
Main Outcome Measures. Accuracy of matching optic discs with their correspond-
ing visual field and of classifying as healthy or glaucomatous. Intraobserver agree-
ment (κ).
Results. The overall accuracy of ophthalmologists for correctly matching stereo-
scopic optic disc photographs to their visual fields was 58.7%. When incorrectly 
matched, the observers generally overestimated the visual field severity (p<0.001), 
notably in eyes with early glaucoma. The intraobserver agreement was on average 
moderate (0.52).
Conclusions. European ophthalmologists correctly matched stereoscopic optic 
disc photographs to their corresponding visual field in only approximately 59% of 
cases. In most mismatches, the clinicians overestimated the visual field damage.
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InTroduCTIon
Judgement of both the optic disc and the visual field are important mainstays in 
diagnosing and managing glaucoma. In a previous study, the European Optic Disc 
Assessment Trial (EODAT), we found that general ophthalmologists have difficulty 
in correctly classifying optic discs as healthy or glaucomatous (diagnostic accuracy 
of 80.5%).1 More so, they were outperformed in correctly classifying eyes by struc-
tural measurements made with scanning laser polarimetry (SLP) and scanning laser 
tomography (SLT), with a diagnostic accuracy of 93.2% and 89.8%, respectively.1 
This confirms other, smaller, studies into the ability of ophthalmologists to discrimi-
nate between healthy and glaucomatous eyes.2-7 Typically, glaucoma diagnosis and 
management are currently based on a combination of functional and structural 
measurements. The ophthalmologist needs to be able to combine and match all 
clinical information, including the visual fields and optic discs. If discs and visual 
fields match, clinicians may confidently diagnose or stage a glaucomatous disc. On 
the other hand, if they don’t match, the diagnosis is far from ruled out and structure 
analysis of the optic disc or retinal nerve fiber layer may provide further informa-
tion. This study explores the ability of ophthalmologists across Europe to match 
stereoscopic optic disc photographs to visual fields. In addition, we compared the 
diagnostic accuracy of the participating ophthalmologists of the present study with 
their own diagnostic accuracy previously obtained in the EODAT, using the same 
dataset.
MeThods
In the current trial, we used the same dataset of stereoscopic photographs of optic 
nerve heads (ONHs) as we did in the EODAT. In the EODAT, the observers were 
asked to grade an ONH as normal or as glaucomatous. The same ophthalmologists 
who responded in the EODAT were invited to participate in this trial. In the current 
trial all ONH photographs were presented together with a choice of 4 visual field 
tests, normal or with varying amounts of glaucomatous visual field loss: mild, mod-
erate and advanced. These 4 visual fields included the corresponding visual field of 
the imaged eye as well as 3 other randomly chosen visual fields. All observers were 
asked to choose the corresponding visual field from the 4 presented visual fields.
Ophthalmologists
We invited 260 ophthalmologists in 11 countries across Europe (the 5 bigger ones 
[France, Germany, Italy, Spain, and the United Kingdom] and 6 smaller ones [Aus-
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tria, Belgium, Finland, Greece, Hungary, and The Netherlands]), to participate in 
this study. They all received letters in their native tongue, explaining the aim of 
the study, the estimated time their participation would take, and the anonymous 
nature of the study. They were also promised to receive a small gift (book) upon 
completion. Those who wished to participate returned a reply card. The positive 
respondents then received by courier mail a package consisting of 1) 110 stereo-
scopic optic disc slides, 2) a viewer (Asahi Pentax Stereo Viewer II, Hoya corpora-
tion, Tokyo, Japan or a similar generic viewer, because the Asahi Pentax viewers 
were in short supply and no longer commercially available), 3) a book with the 
visual fields, in which 4 fields per disc were presented half the regular size on facing 
pages (2 per page), 4) a score sheet, and 5) short instructions in their native tongue. 
All logistics were handled by a clinical research organization (MediTech Strategic 
Consultants B.V., Vaals, The Netherlands).
The ophthalmologists who were invited to participate were those who had taken 
part in the EODAT. We aimed to include approximately half of the invited ophthal-
mologists. In the United Kingdom, almost all ophthalmologists identify themselves 
by subspecialty interest, therefore we selected those with a glaucoma subspecialty 
interest.
Stereoscopic optic nerve head photographs
The stereoscopic photographs that we used in the present study were the same as 
previously described.5 In short, the set consisted of slides of ONHs that had been 
photographed with a simultaneous stereoscopic fundus camera (TRC-SS2, Topcon 
Medical Systems, Inc., Paramus, NJ, USA) at a 15° field of view. Only high quality 
images were used. We took images of 40 healthy eyes, 48 eyes with glaucoma, 
and also 6 with ocular hypertension. These were selected from a cohort of patients 
and controls who had been originally recruited for an ongoing longitudinal glau-
coma study at the Rotterdam Eye Hospital. Nine photographs of glaucomatous 
eyes and of 7 healthy eyes were randomly selected and duplicated for assessing 
intraobserver agreement, totaling 110 stereophotographs. The sequence of the 
photographs was randomized and for each grader presented in the same order. 
To better estimate ONH size, reference slides of healthy, small (5th percentile), 
medium (50th percentile), and large (95th percentile) ONHs were provided.
Patient characteristics and in- and exclusion criteria have been described previ-
ously.1 In short, all subjects were of white ethnic origin and had a best-corrected 
visual acuity of 20/40 or better. All subjects had reproducible and reliable visual 
fields with standard automated perimetry (SAP, Humphrey Field Analyzer II, white-
on-white 24-2 program, Carl Zeiss Meditec AG, Jena, Germany). The healthy 
subjects all had normal visual fields, that is, a glaucoma hemifield test (GHT) within 
69
E
uro
p
ean Structure A
nd
 Functio
n A
ssessm
ent Trial (E
SA
FA
T)
5
normal limits and no nerve fiber bundle visual field defects in the total and/or pat-
tern deviation probability plots. They had healthy-looking ONHs, as assessed by 
one of the glaucoma specialists at the Rotterdam Eye Hospital, and an intraocular 
pressure of ≤ 21 mmHg in both eyes. In the glaucomatous eyes, the disease was 
diagnosed by one of 4 glaucoma specialists of the Rotterdam Eye Hospital based 
on a glaucomatous appearance of the ONH (with notching or thinning of the neu-
roretinal rim, possibly with disc hemorrhages) and a matching defect with SAP. We 
classified the glaucoma patients by the severity of their visual field damage based 
on their mean deviation (MD; mild, MD ≥-6 dB [n=27]; moderate, -12 dB ≤ MD <-6 
dB [n=13]; severe, MD <-12 dB [n=8]).
The research adhered to the tenets of the Declaration of Helsinki. The institu-
tional human experimentation committee had approved the research. Informed 
consent was obtained from the subjects after explanation of the nature and pos-
sible consequences of the study.
Visual field tests
For each presented optic disc, the participating ophthalmologists were asked 
to choose between 4 visual fields of which only 1 was the corresponding visual 
field. The visual fields were always presented in order of increasing disease sever-
ity, i.e. a normal and a mild, moderate and advanced glaucomatous visual field. 
The visual fields used as an alternative choice to match the ONH, were selected 
from the other included eyes, as follows. Firstly, the fields were divided into right 
and left eyes. Secondly, fields were grouped by disease severity, i.e., healthy, mild 
glaucoma (MD ≥-6 dB), moderate glaucoma (-12 dB ≤ MD <-6 dB) and advanced 
glaucoma (MD <-12 dB). Thirdly, we randomly assigned eyes to 2 groups for dif-
ficulty of interpretation, based on the location of the defect in the visual field. One 
group contained eyes in which all 3 glaucomatous visual fields contained defects 
in the same hemifield, i.e. superior or inferior (Difficulty type 1). The second group 
contained 3 glaucomatous visual fields that were randomly selected, regardless of 
the location of the glaucomatous defect (Difficulty type 2). Because all visual fields 
included to this trial also served as an alternative choice for other visual fields, most 
of them were used several times for this purpose. There was 1 type of visual field 
loss that was not represented by the included glaucoma patients: mild glaucoma 
with an inferior scotoma. To have an alternative choice for moderate and advanced 
glaucomatous inferior scotomata we included such a visual field from a subject 
from another study at our hospital.
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Data analysis
For each observer, we calculated the overall matching accuracy. Overall matching 
accuracy was defined as the number of correctly matched eyes divided by the total 
number of examined eyes. For each observer, we also calculated the matching 
sensitivity per group of disease severity (mild, moderate and advanced glaucoma, 
respectively) and the matching specificity (percentage correctly matched healthy 
discs). In addition, the overall matching accuracy was calculated for each country. 
When an optic disc was incorrectly classified, we calculated the level of mismatch-
ing. Levels were stratified by disease severity. When for instance a healthy eye was 
scored as an advanced glaucomatous eye, the level of mismatching was +3.
The matching intraobserver agreement in classifying disease severity was ex-
pressed as κ. The values for κ were classified as follows: ≤0.20, poor; 0.21 to 0.40, 
fair; 0.41 to 0.60, moderate; 0.61 to 0.80, good; and ≥0.81, very good.8
In the EODAT, all observers were asked to score every optic disc slide either 
as healthy or glaucomatous. We have determined this score for the current trial 
as well, by pooling the 3 glaucoma groups. We compared the outcome of every 
observer who had participated and had returned fully completed score sheets in 
both studies (n=100).
The data of eyes with ocular hypertension were not analyzed in the present study 
as they had merely been added to present a continuum of glaucomatous damage.
We used an analysis of variance (ANOVA) to evaluate differences in measure-
ments between groups and countries. For differences in dichotomous variables 
between groups, we used the Pearson χ2 test. We used the Kruskal-Wallis test to 
evaluate differences in level of mismatching. To compare the outcome of labeling 
as healthy or glaucoma per observer with the EODAT, we used paired t-tests. In 
the present study, a p-value of less than 0.05 was considered statistically significant. 
Statistical analyses were performed with PASW Statistics 18 for Windows (release 
18.0.0, 2009, IBM SPSS Statistics, New York, USA).
The demographics of the healthy subjects and glaucoma patients have been 
presented in table 1.
resulTs
Of the 260 ophthalmologists that were invited, 109 (39.5%) agreed to participate. 
Figure 1 shows the number of those invited per country and the number of par-
ticipating ophthalmologists. All participants returned completed score sheets. The 
rate of responders varied considerably between countries. The highest response 
rate was in Greece (72.7%). Italy showed the lowest response rate of 16.7%.
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Matching Accuracy
The overall matching accuracy of the 109 participating ophthalmologists for correctly 
matching stereoscopic optic disc photographs to their visual fields was 58.7%. The 
matching sensitivity for glaucomatous eyes was 30.9%, 51.4% and 75.8% for mild, 
moderate and advanced glaucoma, respectively. The matching specificity was 76.4%. 
None of the ONH stereo-slides was matched correctly by all observers. One mild 
Table 1 Demographics of Healthy Subjects and Glaucoma Patients
Unit Healthy 
subjects 
(n=40)
Glaucoma Patients (n=48) P
Mild 
(n=27)
Moderate 
(n=13)
Advanced 
(n=8)
Age (SD; range) yrs 59 (12;30-82) 63 (10;46-82) 63 (10;45-81) 54 (12;30-68) 0.16
Gender (male) (%) NA 19 (48) 14 (52) 7 (54) 5 (63) 0.88
MD (SD; range) dB 0.07
(0.92; -1.55 to 
2.04)
-2.14
(1.72; -5.94 to 
2.26)
-8.72
(1.42; -10.99 
to -6.70)
-18.26
(4.01; -22.26 
to -12.55)
<0.001
Randomized eye (right) (%) NA 21 (53) 6 (22) 7 (54) 5 (63) 0.05
dB = decibel; MD = mean deviation; NA = not applicable; SD = standard deviation
Differences between the groups were tested for statistical significance with an analysis of variance for 
continuous variables and the Pearson chi-square test for dichotomous variables.
Figure 1 Histogram of the number of invited (left) and participating (right) ophthalmologists per 
country. AT: Austria; BE: Belgium; FI: Finland; FR: France; DE: Germany; GR: Greece; HU: Hungary; IT: 
Italy; NL: The Netherlands; ES: Spain; UK: United Kingdom.
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glaucomatous ONH was correctly scored by only 3 observers (2.8%). An analysis of 
variance showed that there were statistically significant differences in the matching 
accuracy between the various countries (p<0.05), except for the matching sensitivity 
for advanced glaucomatous eyes (p=0.192). The participants of the United Kingdom 
(glaucoma subspecialist group) performed better than the general ophthalmologists 
of the other countries. This was statistically significant for 7 other countries (p<0.05), 
except for Austria, Finland and The Netherlands. The results of correctly matching 
ONHs to their appropriate visual field have been presented in Table 2.
Mismatching
When the observers incorrectly matched the ONH to the visual field, they tended to 
overestimate the severity of visual field damage (Kruskal-Wallis test, p<0.001). Figure 2 
shows the amount of under- and overestimation of the incorrectly scored stereo slides.
The incorrectly scored healthy eyes were, on average, overestimated by 1.33 (SD 
0.60) classes. Mild glaucomatous eyes were overestimated by, on average, 0.65 
(SD 1.22; p<0.001) classes, while moderate and advanced glaucomatous eyes 
were underestimated, by, on average, -0.05 (SD 1.15; p<0.001) and -1.26 (SD 0.54) 
classes, respectively. We found statistically significant differences in the level of 
mismatching between the various countries (Kruskal-Wallis test, p<0.001).
Table 2 Matching Accuracy for correctly matching stereoscopic optic disc photographs to their vi-
sual field by ophthalmologists from various countries, presented for each disease severity.
Observers 
(n)
Overall 
matching 
accuracy (%)
Matching 
Specificity (%)
Matching Sensitivity (%)
Healthy 
(n=40)
Mild
(n=27)
Moderate 
(n=13)
Advanced 
(n=8)
Overall 109 58.7 (51.6) 76.4 (30.6) 30.9 (8.3) 51.4 (6.7) 75.8 (6.1)
Austria 5 63.9 (56.2) 83.5 (33.4) 33.3 (9.0) 53.8 (7.0) 85.0 (6.8)
Belgium 8 57.5 (50.6) 73.4 (29.3) 30.1 (8.1) 52.9 (6.9) 78.1 (6.3)
Finland 3 62.9 (55.3) 90.0 (36.0) 22.2 (6.0) 53.8 (7.0) 79.2 (6.3)
France 10 50.6 (44.5) 68.8 (27.5) 21.9 (5.9) 41.5 (5.4) 71.3 (5.7)
Germany 22 57.6 (50.7) 75.9 (30.4) 32.0 (8.6) 49.3 (6.4) 66.4 (5.3)
Greece 8 54.7 (48.1) 67.8 (27.1) 33.8 (9.1) 44.2 (5.8) 76.6 (6.1)
Hungary 7 53.4 (47.0) 70.4 (28.1) 30.2 (8.1) 42.9 (5.6) 64.3 (5.1)
Italy 4 54.0 (47.5) 68.8 (27.5) 34.3 (9.3) 38.5 (5.0) 71.9 (5.8)
The Netherlands 8 61.4 (54.0) 80.3 (32.1) 33.3 (9.0) 50.0 (6.5) 79.7 (6.4)
Spain 12 53.7 (47.3) 67.5 (27.0) 25.3 (6.8) 50.0 (6.5) 86.5 (6.9)
United Kingdom 22 67.8 (59.7) 87.8 (35.1) 35.4 (9.6) 65.7 (8.6) 80.7 (6.5)
Overall matching accuracy, matching specificity and matching sensitivity are presented as mean 
(number).
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Difficulty
The ophthalmologists had somewhat more trouble in correctly matching the ONH 
to the appropriate visual field when the alternative choices all showed a glaucoma-
tous defect in the same hemifield (Difficulty Type 1) than when the location of the 
alternative scotomata had been randomized (Difficulty Type 2; p=0.04). The overall 
matching accuracy was 57.0% and 60.4%, respectively, for Difficulty Types 1 and 2. 
Within Difficulty group Type 1, any mismatches were equally balanced for over- and 
underestimating the severity of glaucoma (p=0.09).
Matching intraobserver agreement
The matching intraobserver agreement within the ESAFAT data, expressed as κ, 
was on average moderate (0.52; SD 0.23), ranging between -0.04 and 1.00.
Comparison of ESAFAT with EODAT
We compared the accuracy of classifying optic discs as healthy or glaucomatous 
for every individual ophthalmologist participating fully in both the current trial and 
the EODAT (n=100); for each, we also determined the intraobserver agreement.
Diagnostic accuracy
The overall accuracy and the specificity of the participating ophthalmologists were 
statistically significantly higher in the EODAT than in the ESAFAT (p≤0.009). Their 
Figure 2 Histogram of the percentage of mismatched optic disc stereo slides to their correspond-
ing visual field. The level of mismatching represents the under- or overestimation of the visual field 
damage stratified per disease severity.
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sensitivity for glaucomatous discs was higher in the ESAFAT (p<0.001). The par-
ticipants of the United Kingdom (glaucoma subspecialist group) performed better 
than the general ophthalmologists of the other countries in both the ESAFAT and 
EODAT (p<0.023 in all countries, except for Austria, Finland and The Netherlands 
in the ESAFAT and Austria, Finland and Spain in the EODAT). The overall diagnostic 
accuracy of all ophthalmologists together and that of the participants of the United 
Kingdom has been presented in Table 3.
Intraobserver agreement
The intraobserver agreement of optic disc classification in the ESAFAT, expressed 
as κ, was on average moderate (0.57; SD 0.25), and worse than in the EODAT, which 
was good (0.71; SD 0.23; paired t-test; p<0.001).
dIsCussIon
Ophthalmologists across Europe correctly matched stereoscopic photographs of 
healthy and glaucomatous optic discs of various stages of the disease to their cor-
responding visual field in only approximately 59% of cases. In misclassifications of 
early glaucomatous ONHs, the severity of glaucomatous visual field damage was 
more often overestimated than underestimated.
The conditions of our current trial were almost ideal. The ophthalmologists were 
asked to grade stereo-photographs of good quality and match them to reliable 
visual fields with no artifacts. This contrasts markedly with assessing optic discs 
and visual fields in everyday clinical care, in which both the visual fields and the 
stereoscopic visibility of the optic discs may be suboptimal. In addition, we pre-
sented the observers four visual fields per optic disc photograph to choose from, 
in arbitrarily selected classes, and selected only perimetric glaucoma cases. These 
experimental conditions may have yielded an overestimation of the performance 
of general ophthalmologists in Europe under real life circumstances.
In the current investigation we re-targeted our previous (EODAT) ophthalmolo-
gist population1, to see whether their classification performance was improved. 
Despite the statistically significant, but small differences between the two trials, 
it remains somewhat speculative whether the presence of visual fields weakens 
or strengthens general ophthalmologists’ ability to diagnose glaucoma. Though 
classification accuracies were statistically significantly different in the two investiga-
tions, the outcome of the current trial confirms the outcome of EODAT1, i.e. that 
general ophthalmologists classify optic discs only moderately well for detecting 
glaucoma, especially in the early stage of the disease. It is likely that whenever 
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clinical classifi cation of visual fi elds and optic discs correspond, clinicians will feel 
more confi dent about their judgment than in cases when structure and function 
are thought to disagree. Visual fi elds that may look relatively good, compared to 
the optic discs, may even put the clinician off guard. However, it is unclear to what 
extent these presumed effects might impact on clinical decision making.
Another interpretation of our fi ndings is that the participating ophthalmologists 
were suboptimally trained. Years of training leads to an improved judgment of 
optic discs (Zeyen T et al., Invest Ophthalmol Vis Sci 2011,43:4169) 9,10, as was 
also illustrated by the modest difference between the diagnostic accuracy of the 
trained UK glaucoma specialists and the general ophthalmologists in our current 
study, as well as in the EODAT trial. On the other hand, even glaucoma specialists 
may have diffi culties in judging optic discs.6,7,11 Perhaps both general ophthalmolo-
gists and glaucoma specialists require better or more training. Several glaucoma 
associations worldwide have been taking effort to improve the ability of (general) 
ophthalmologists and residents to judge optic discs and visual fi elds by organizing 
various educational programs. Education and training of ONH judgment (Zeyen T 
et al., Invest Ophthalmol Vis Sci 2011,43:4169) 9,10,12,13 as well as of visual fi eld testing 
at an appropriate re-test frequency14 are most likely to yield optimal monitoring of 
glaucoma. Our fi ndings do not necessarily apply to other parts of the world, where 
training programs may be quite different from those in Europe, which already hap-
pen to be quite heterogenic.
In conclusion, we think that both clinical ONH judgment and evaluation of visual 
fi eld test results remain important mainstays in daily clinical care. Continuous edu-
cation of general ophthalmologists in both areas is therefore particularly important.
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absTraCT
Purpose. Progression of glaucoma can be monitored by assessment of functional 
changes in visual fields and structural changes of the optic nerve head (ONH) and 
retinal nerve fibre layer. This study determines the association between those 
techniques used most in daily glaucoma care for detecting glaucoma progression; 
i.e. standard automated perimetry (SAP) and clinical assessment of the ONH; to 
explore the latter, we use stereoscopic photographs. It also investigates any differ-
ences among various eye-care professionals in their ability to detect progression 
on sequential stereoscopic ONH photographs.
Methods. Stereoscopic ONH photographs of 67 glaucomatous eyes were assessed 
by 4 optometrists, 4 ophthalmology residents, 4 general ophthalmologists and 4 
glaucoma specialists. Their scores were compared with the outcome of progres-
sion analysis software on SAP (Guided Progression Analysis (GPA); Humphrey Field 
Analyzer II-i, Carl Zeiss Meditec, Dublin, USA).
Results. There were no statistically significant differences between the progression 
detected by the GPA and that by the professionals, but there was no association 
found (p=0.096). Inter observer agreement was fair in all professions and highest 
among glaucoma specialists (intra class correlation coefficient = 0.302). The intra 
observer agreement ranged between κ -0.333 and 1.0 (average 0.474).
Conclusions. In this study on glaucomatous progression, there was poor agree-
ment between visual fields and ONH changes scored by eye care professionals. 
The overall accuracy for the use of stereoscopic photographs in detecting glauco-
matous progression was poor.
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InTroduCTIon
In daily glaucoma practice, the appearance of the optic nerve head (ONH) is one 
of the first aspects a clinician judges, next to the intraocular pressure (IOP) and the 
visual field. Although most ophthalmic clinicians assess multiple ONHs per day, 
general ophthalmologists poorly judge an ONH as healthy or glaucomatous.1 They 
are even outperformed in correctly classifying eyes by devices measuring structural 
glaucomatous change, such as scanning laser polarimetry (SLP) and scanning laser 
tomography (SLT).1 The assessment of an ONH for making a diagnosis is sensitive 
to subjective judgment, and judging it for progression detection probably also.1-4
None of the various methods for detecting structural glaucomatous progression, 
such as SLP, SLT and optical coherence tomography, is generally accepted as a 
gold standard.5 In a study comparing two structural methods to detect progres-
sion, stereoscopic ONH photography and SLT, there was poor agreement between 
the two.6 Substantial variability in the interpretation of glaucomatous progression 
in ONH photographs exists.7;8 Arguably, assessment of the ONH by stereo-photo-
graphs most closely reflects the clinical setting.9
Glaucomatous progression detected by visual fields is usually seen as the gold 
standard. However, the agreement between expert clinicians using serial printouts 
of the Humphrey Field Analyzer (HFA) to detect progression turns out to be poor.10 
Since the introduction of progression analysis software, such as the Glaucoma 
Progression Analysis on the Humphrey Field Analyzer, a more sophisticated way of 
detecting progression is introduced, leading to a higher interobserver agreement. 5
In monitoring glaucoma, determining whether structural or functional progression 
has occurred is an important challenge.11;12 The exact relationship between structure 
and function in glaucoma has not yet been clarified.13-16 Apparently, structural progres-
sion often precedes functional progression.11;15;17-20 On the other hand, one of the larg-
est trials in measuring conversion from ocular hypertension into glaucoma, the Ocular 
Hypertension Treatment Study, found that conversion to glaucoma was first detected 
in ONH photography in around 50% and by visual field testing in approximately 40%.21 
In earlier studies on progression detection on visual fields, progression was detected 
by means of extensive, complicated or nowadays outdated analyses of the visual 
fields.17;18;21-24 In this study, we therefore implemented the latest progression analyses 
in standard automated perimetry and explored their ability to detect glaucomatous 
progression in visual fields. Because ONH assessment and visual field testing is per-
formed most often in daily glaucoma care, we explored both the progression detec-
tion in visual fields and the clinical assessment of glaucomatous progression in ONH 
stereo-photographs. This study also explores any differences among various Dutch 
eye-care professionals in judging progression on these ONH stereo-photographs.
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MeThods
Subjects
Seventy-two glaucomatous eyes were selected from a cohort of patients in an ongo-
ing prospective, longitudinal imaging study at the Rotterdam Eye Hospital (REH) that 
adheres to the tenets of the Declaration of Helsinki and that was approved by the 
Medical Ethics Committee of the Erasmus Medical Centre, Rotterdam, The Nether-
lands. Informed consent was obtained from all subjects. All subjects were Caucasian 
and had a best-corrected visual acuity of 20/40 or better. None of them had a history 
of intraocular surgery (except for uncomplicated cataract or glaucoma surgery) or of 
coexisting ocular disease. Their treatment for glaucoma was part of standard clinical 
care. Glaucoma had been diagnosed by a glaucoma specialist based on the appear-
ance of the ONH and a corresponding reproducible visual field defect with SAP.
For the current study, only those subjects from the cohort were selected with 
at least a five year interval between the first and last stereo ONH photographs, 
leading to the amount of 72 eligible eyes. Stereo ONH photographs were taken 
once or twice yearly and SAP visual fields were taken every 6 months. Baseline 
ONH stereo-photographs as well as the last ones were taken at the same visit as 
the visual field tests.
Stereoscopic ONH photographs
The ONHs were photographed with a simultaneous stereoscopic fundus camera 
(TRC-SS2, Topcon Medical Systems Inc., Paramus, NJ, USA) with a 15 degree field 
of view. A total of 8 eyes was randomly selected and included twice to test the intra 
observer agreement. In all, we had a set of 80 pairs of stereoscopic ONH slides.
Clinical assessment of stereoscopic ONH photographs
The stereoscopic ONH slides were evaluated by a total of 16 observers: 4 op-
tometrists, 4 senior residents in ophthalmology, 4 general ophthalmologists and 
4 glaucoma specialists, who all worked at the REH. The observers received the 
ONH slides and 2 viewers (Asahi Pentax Stereo Viewer II, Hoya Corporation, Tokyo, 
Japan). The observers also received a score sheet that briefly explained which signs 
of progression to look for: any narrowing of the neuroretinal rim, changes in defects 
of the RNFL, generalised thinning of the RNFL, the presence of disc haemorrhages, 
changes to the position of the blood vessels, as well as changes in any peripapil-
lary atrophy. The observers individually classified the pairs of ONH slides as either 
progressing or stable. The slide-pairs were presented in chronological order, and 
the observers were informed as such. This chronological order of slides was used 
to mimic the clinical setting as much as possible.
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Standard Automated Perimetry (SAP)
SAP was obtained by HFA (Humphrey Field Analyzer II, Carl Zeiss Meditec AG, 
Jena, Germany) by either using the 24-2 Full Threshold (FT) or the 24-2 Swedish 
Interactive Thresholding Algorithm (SITA) strategies or a combination of both. Dur-
ing the course of this trial, we decided to use the Sita-Standard (SS) test paradigm 
instead of the Full-Threshold (FT) test paradigm, since it was thought to improve 
the quality and shorten the test-time of the visual fields, without compromising 
their outcome.25;26 All subjects had reproducible VF defects. Only reliable tests 
were included. To that end, all of the following criteria had to be met: fixation 
losses FT ≤ 20%, SITA ≤ 7%; false positive and negative rate FT ≤ 33%, SITA ≤ 7%.
Glaucomatous progression of the VF was determined by using the visual field 
index (VFI) trend analysis of the Glaucoma Progression Analysis (GPA) software on 
the HFA (HFA-II-i, Software Version 4.2, CZM, Dublin, CA, USA), expressed in %/
year. We randomly selected 14 VFs for the GPA whenever more tests were eligible, 
because 14 is the maximum for the GPA. The 2 baseline exams, as well as the final 
one were always included. The eyes were classified as progressing if the slope of 
the VFI was negative and statistically significant over time (p < 0.05).
Data analysis
The statistical analyses were performed with SPSS for Windows (release 15.0, 2005, 
SPSS inc., Chicago, IL, USA). McNemar’s tests were used to calculate if there were 
statistically significant (p<0.05) differences between the progression determined 
by GPA or by assessment of eye-care professionals. The qualification of progres-
sion during the assessment by the professionals, was measured by a census of 75% 
of the professionals. Spearman’s Rho was used to measure if there was a linear 
relation between the rate of progression and the number of eye-care professionals 
who detected progression. The intra observer agreement was expressed as κ. The 
values for κ were classified as follows: ≤ 0.20, poor; 0.21 to 0.40, fair; 0.41 to 0.60, 
moderate; 0.61 to 0.80, good; and ≥ 0.81, very good.27 The inter observer agree-
ment was expressed as an intra class correlation coefficient (ICC). The values for 
ICC were classified as described earlier for κ. The ICC was calculated for the overall 
group and per group of eye-care professionals. Sensitivities and specificities were 
calculated for each individual observer, with the GPA outcome as a reference.
The ONH photographs of 5 subjects were deemed to be of too poor quality by at 
least 6 of the observers. These photographs were therefore excluded from further 
analysis, so that a total of 67 eyes remained.
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resulTs
More than half (52.2%) of our cohort of 67 glaucomatous eyes showed progression 
based on the GPA of the visual fields, using the visual field index (VFI in %/year). 
The rate of progression of progressing eyes was significantly higher than that of 
non-progressing eyes (p<0.0001). The demographics of the glaucomatous patients 
are shown in Table 1. In addition, we explored the correlation between the rate 
of progression and the number of professionals who detected progression in the 
ONH stereo-photographs (Fig. 1).
The correlation between the rate of field progression and the number of observers 
that detected ONH progression was tested by using Spearman’s Rho and turned 
out to be statistically non-significant (-0.286, p=0.096).
Observer agreement
The overall intra class correlation (ICC) for inter observer agreement was 0.168, indicating 
poor agreement among all observers. Each of the various professionals scored a fair 
agreement within their respective groups (Table 2). The intra observer agreement was on 
average moderate (κ = 0.474; Table 2). Nevertheless there was a great range between 
the different professions and professionals. Some observers mentioned that there were 
slides duplicated. It is possible they, and others as well, therefore purposely reassessed 
these photographs, thereby checking what they had previously answered, to be more 
consistent. This might have adversely affected the reliability of the intra observer repro-
ducibility. Nevertheless, it was generally quite poor. It may, however, possibly explain why 
some observers reached a perfect intra-observer agreement with a κ of 1.0.
Table 1 Demographics of glaucomatous eyes (n=67)
 Unit Subjects
Age at inclusion Years (SD;range) 59 (10; 29-77)
Gender % male 63
  Glaucomatous eyes
Time between photos Months (SD;range) 88 (8; 62-119)
MD t(0) dB (SD) -8.22 (5.7)
MD t(end) dB (SD) -9.94 (5.6)
GPA - Progression (negative slope significant p<0.05) Number (%) 35 (52.2)
Rate of progression Overall (Mean %/year) (± 95% CI) -0.7 (± 0.8)
 Progressing eyes (Mean %/year) (± 95% CI) -1.3 (± 1.2)
 Non-progressing eyes (Mean %/year) (± 95% CI) -0.1 (± 0.4)
Abbreviations: dB = decibel, MD = mean deviation, SD = standard deviation, GPA = Glaucoma 
Progression Analysis; CI = confidence interval
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Sensitivity and specificity
The mean sensitivity for the observers in detecting progression on ONH photo-
graphs compared to the GPA II was 0.531 [SD 0.13]. The mean specifi city was 0.604 
[SD 0.10]. The sensitivity and specifi city of all individual observers have been shown 
in Table 3.
dIsCussIon
We found no correlation between the rate of progression and the number of 
professionals that detected progression on sequential stereoscopic ONH photo-
graphs. This may not be very surprising, because several studies have shown that 
Rate of Progression (VFI %/year) (p < 0.05)
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Figure 1 The rate of progression of the visual fi eld index (VFI, statistically signifi cant) as scored by 
the glaucoma progression analysis (GPA) software on visual fi elds versus the number of professionals 
who detected progression based on optic nerve head stereo photographs.
Table 2 Observer agreement for the various professions in assessing stereoscopic ONH photo-
graphs
 Inter observer agreement Intra observer agreement
 ICC Mean κ Range
Optometrists 0.252 0.750 0.500 - 1.000
Residents in Ophthalmology 0.264 -0.008 -0.250 - 0.467
Ophthalmologists 0.246 0.319 -0.333 - 1.000
Glaucoma Specialists 0.302 0.835 0.588 - 1.000
Overall 0.168 0.474 -0.333 - 1.000
Abbreviations: ICC = intra class correlation
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the correlation between structure and function in glaucoma is generally weak, and 
also in glaucomatous progression.13-15;20;28;29 In our study, the progression seen on 
the ONH stereo-photographs did not match the progression scored by the GPA. 
In fact, there was no relation at all. For instance, there was a case with an ROP of 
-4.0, which only half of the observers scored as structural ONH progression. On the 
other end of the scale, there was a case in which about 75% of the professionals 
scored ONH progression and the GPA didn’t show any progression. This outcome 
confirms other studies, suggesting that structural and functional progression are 
independent indicators of progressive disease.13 Therefore, it is probably wise to 
use both structural and functional measurements clinically, to avoid missing any 
progressing cases.
Because we used the GPA progression criterion as a reference standard, the 
sensitivity and specificity of ONH photographs progression assessments were, not 
surprisingly, disappointing, given the poor correlation between structural and func-
tional progression. The poor sensitivity and specificity of ONH assessments might 
therefore probably be seen as indicators of a poor correlation between structural 
and functional progression28;29, rather than as poor performance of the observers. 
Nevertheless, a possibly poor performance should also be taken into account. 
Friedman et al. found that 40 percent of all stereoscopic ONH photographs that 
were classified as progressing, were in fact replicates of baseline photographs, 
Table 3 Sensitivity and specificity for different observers in assessing stereoscopic ONH photo-
graphs
 Sensitivity Specificity Overall accuracy
Optometrist 1 0.343 0.531 0.437
Optometrist 2 0.486 0.594 0.540
Optometrist 3 0.571 0.500 0.536
Optometrist 4 0.371 0.719 0.545
Resident 1 0.543 0.688 0.615
Resident 2 0.571 0.375 0.473
Resident 3 0.686 0.750 0.718
Resident 4 0.600 0.594 0.597
Ophthalmologist 1 0.400 0.594 0.497
Ophthalmologist 2 0.486 0.688 0.587
Ophthalmologist 3 0.706 0.469 0.587
Ophthalmologist 4 0.571 0.656 0.614
Glaucoma Specialist 1 0.771 0.594 0.683
Glaucoma Specialist 2 0.364 0.710 0.537
Glaucoma Specialist 3 0.429 0.625 0.527
Glaucoma Specialist 4 0.600 0.581 0.590
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which indicates that the judgment of such photographs is quite poor, even by 
glaucoma specialists.8 Clinically using both structural and functional methods 
of progression detection runs the risk of overcalling, since both methods show 
significant measurement variability; this may be avoided by setting high specificity 
criteria for each, which may in part be achieved by requiring progression to be 
reproducible.
We found a fair agreement in detecting progression in sequential ONH pho-
tographs between eye care professionals within their various groups. Jampel et 
al., in a group of glaucoma specialists, found somewhat worse results, which may 
perhaps be explained by differences in methods; one such difference was that 
they used stereoscopic ONH photographs that were taken sequentially, instead 
of simultaneously (as in our study).8 In our group as a whole, the inter observer 
agreement for ONH progression detection was poor. We decided to present the 
photographs in chronological order and inform the observers about the sequence. 
The chronological order might have affected the results.30 The group of glaucoma 
specialists in our study had a slightly better inter observer agreement than the 
other groups of observers. For making a diagnosis of glaucoma on stereoscopic 
ONH photographs, it was also observed that glaucoma specialists generally did 
better than other eye care professionals with less training and experience.31 This 
may suggest that training and experience improve the consistency of detecting 
both structural damage and progression in stereoscopic ONH photographs.
Although we had a small sample size for calculating the intra observer agreement, 
we found that the intra observer agreement of detecting glaucomatous progres-
sion varied widely across observers, which confirms other studies.4;9 This means that 
some observers are very consistent and others are not. We think that few clinicians 
are aware of their own consistency in judging glaucomatous ONH progression. 
Perhaps training could improve that consistency. We found that the optometrists 
and glaucoma specialists did better than the other groups of observers, perhaps 
because they were more experienced. We think, however, that clinicians that do 
not regularly assess simultaneous stereoscopic ONH photographs will be even 
less likely to consistently detect structural glaucomatous progression, when they 
resort to less accurate methods, e.g., descriptions or drawings of the ONH in the 
medical records. This probably calls for objective structural measures for detect-
ing glaucomatous progression. Although we are unaware how many clinicians use 
stereoscopic ONH photographs for follow-up in their glaucoma management, 
we think this number is relatively small. Probably many more make descriptions 
or (annotated) drawings, or simply write down cup-to-disc (C/D) ratios. To our 
knowledge, the accuracy of these methods for detecting glaucoma progression 
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has never been formally assessed, although baseline C/D ratios have been shown 
to be predictive of future visual fi eld loss.32;33
In daily care, next to the IOP, the appearance of the ONH and the visual fi eld 
are the standard means to monitor glaucoma. This study confi rms earlier evidence 
of the generally poor performance of eye care professionals to properly judge an 
ONH as progressing or not, let alone determining the rate of progression. By ap-
plying the latest commercially available progression algorithms on visual fi elds, 
we used the analyses resembling standard basic, modern daily glaucoma care. 
Even with the latest visual fi eld progression algorithms, the correlation with ONH 
assessment was strikingly poor. The use of optical coherence tomography (OCT), 
a structural measurement technique currently implemented more often in daily 
glaucoma practice, may be promising. Several studies have shown OCT to predict 
progression on visual fi elds.34-36 The thickness of the RNFL35;36 as well as the thick-
ness of the macular ganglion cell complex34 predicts visual fi eld loss in the following 
years. Taken together, these results suggest the potentially important clinical role 
of OCT measurements in glaucoma care; they appear to hold considerably greater 
promise than the clinical assessment of the ONH by an ophthalmologist.
In conclusion, our results confi rm earlier work that there is a poor agreement be-
tween structural and functional progression detection in the clinical assessment of 
serial stereoscopic ONH photographs and visual fi elds in glaucoma. To our dismay, 
the latest version of the GPA did not markedly improve this correlation. In addition, 
we observed that the inter observer agreement was poor to fair for judging ONH 
photographs. The intra observer agreement for ONH photographs was also highly 
variable and sometimes alarmingly poor. In general, glaucoma specialists judged 
ONH photographs for progression detection slightly more consistently than did 
less experienced eye care professionals.
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absTraCT
Purpose. To investigate transient focal microcystic retinoschisis in glaucomatous 
eyes in images obtained with several imaging techniques used in daily glaucoma 
care.
Methods. Images of 117 glaucoma patients and 91 healthy subjects participat-
ing in a large prospective follow up study into glaucoma imaging were reviewed. 
Participants were measured with spectral domain optical coherence tomography 
(SD-OCT), scanning laser polarimetry (SLP), scanning laser tomography (SLT) and 
standard automated perimetry (SAP). The presence of a focal retinoschisis in 
SD-OCT was observed and correlated to SLP, SLT and SAP measurements, both 
cross-sectionally and longitudinally.
Results. Seven out of 117 glaucoma patients showed a transient, localised, peri-
papillary, heterogeneous microcystic schisis of the retinal nerve fiber layer (RNFL) 
and sometimes other retinal layers as well, in SD-OCT. None of the healthy eyes 
showed this phenomenon, nor did any of the other imaging techniques display 
it as detailed and consistently as did the SD-OCT. SAP showed a temporarily de-
creased focal retinal sensitivity during the retinoschisis and we found no signs of 
glaucomatous progression related to the retinoschisis.
Conclusions. Transient microcystic retinoschisis appears to be associated with 
glaucomatous wedge defects in the RNFL. It was best observed with SD-OCT 
and it was absent in healthy eyes. We found no evidence that the retinoschisis 
predicted glaucomatous progression.
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InTroduCTIon
In glaucoma, retinal nerve fibers are damaged and lost, leading to thinning of the 
retinal nerve fiber layer (RNFL).1,2 The thinning of the RNFL can be measured by 
different imaging techniques, such as scanning laser polarimetry (SLP), scanning 
laser tomography (SLT) and optical coherence tomography (OCT).3 The current 
generation OCT, i.e. spectral domain OCT (SD-OCT)4-7, shows a more detailed 
image of all layers of the retina compared to time domain OCT, which potentially 
leads to new insights.
Several recent studies presented cases with peripapillary retinoschisis, imaged 
with SD-OCT.8-13 All studies showed a relation of the retinoschisis with the presence 
of glaucoma. Kahook et al.11 and Lee et al.12 related the retinoschisis also with 
high or fluctuating intraocular pressures. Following a large population for several 
years, Lee et al. were able to observe spontaneous resolution of the retinoschisis. 
Recently, Lee et al. presented alterations of the lamina cribrosa to be associated 
with peripapillary retinoschisis.13 To date, several insights in this newly described 
phenomenon have been presented, but the pathogenesis and the course of the 
retinoschisis remains uncertain. Also, whether the retinoschisis is related to glau-
coma progression and whether it can also be imaged by other techniques used in 
daily glaucoma care, still is unknown.
In the current study, we describe the appearance of this peripapillary retinoschisis 
over time that we observed in SD-OCT images of a subset of subjects participating 
in a large, prospective longitudinal study on glaucoma imaging. We also explore 
the effects of the retinoschisis on the measurements of various other, commonly 
used functional and structural techniques in glaucoma care. In addition, we assess 
a potential correlation between the appearance or disappearance of the retinos-
chisis and glaucomatous progression, measured by several techniques.
MeThods
Participants
This report presents the outcome of reviewing a study cohort of 117 glaucoma pa-
tients and 91 subjects with healthy eyes on the presence of a peripapillary retinos-
chisis. All subjects participated in a longitudinal prospective follow-up study into 
glaucoma imaging. All acquired images that had been taken in 4 successive years, 
were retrospectively reviewed for the presence of any peripapillary retinoschisis.
To be qualified as healthy, a subject was required to have a normal visual field and 
an intraocular pressure of 22 mmHg or less. A normal visual field had, by definition, 
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a Glaucoma Hemifield Test within normal limits and a Mean Deviation (MD) and 
Pattern Standard Deviation (PSD) within their respective 95% confidence intervals. 
Visual fields were considered as glaucomatous if at least two of the following find-
ings were confirmed on the successive visual field: a PSD significant at the 5% 
probability level, a Glaucoma Hemifield Test outside normal limits and a cluster of 
3 or more points below the 5% probability level or 1 individual point below the 1% 
probability level.
Subjects were excluded from participation in the presence of any significant 
coexisting ocular or systemic disease known to possibly affect the visual field (e.g., 
diabetes mellitus), a history of intraocular surgery (except for uncomplicated cata-
ract surgery and glaucoma surgery in glaucoma patients), uncontrollable arterial 
hypertension and secondary glaucoma.
All participants had a best-corrected Snellen visual acuity of at least 20/40 in 
both eyes, a spherical equivalent refractive error between -10.0D and +5.0D, and 
unremarkable findings upon slit-lamp examination, including open angles on 
gonioscopy.
All glaucoma patients were recruited at the Glaucoma Service at the Rotter-
dam Eye Hospital. The healthy subjects were mainly friends and spouses of the 
glaucoma patients who volunteered to participate in the longitudinal study. The 
methods and procedures used in this study adhered to the Declaration of Helsinki. 
Informed consent was obtained from all participants. This study was approved by 
the Medical Ethics Committee of the Erasmus Medical Centre, Rotterdam, The 
Netherlands.
Image Acquisition
All participants were measured with the Spectralis OCT (Heidelberg Engineering 
GmbH, Dossenheim, Germany), an imaging device that features SD-OCT. With 
SD-OCT, the peripapillary areas of both eyes were scanned by means of a volume 
scan of 20 by 20 degrees.
In the same session, all participants were measured with several other imaging 
techniques as well, including SLP (GDxECC [GDx]; Carl Zeiss Meditec inc., Dublin, 
CA, USA) and SLT (Heidelberg Retina Tomograph III [HRT], Heidelberg Engineering 
GmbH, Dossenheim, Germany). All participants also underwent visual field test-
ing (Humphrey Field Analyzer [HFA], Carl Zeiss Meditec Inc., Dublin, CA, USA). All 
measurements were repeated every six months in glaucomatous cases and every 
12 months in healthy cases.
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Analysis
Cross-sectional
Because we incidentally noticed a focal schisis of the RNFL, and sometimes of other 
retinal layers as well, in some of the SD-OCT images, we systematically reviewed 
all images of all participants in the longitudinal study to detect a similar schisis 
in other eyes. The cases that showed the focal retinoschisis were followed over 
time, to evaluate its course. We also explored whether any of the other imaging 
devices allowed us to image the schisis. In addition, we compared the area of 
schisis, measured with SD-OCT, to the corresponding sectors of the visual field, 
using the method introduced by Garway-Heath et al.14 To indicate the presence 
and size of a glaucomatous defect, we counted the number of points below the 
0.5% probability level within the corresponding sector in either the total or the 
pattern deviation probability plot, whichever showed the fewest abnormal points. 
In the GDx, we examined the retardation map. The HRT has no specific parameters 
to quantify RNFL thickness around the optic nerve head (ONH). Therefore, the 
three-dimensional topography image (HRT-3D) was the only way in the HRT to 
quantitatively determine the surface height around the ONH.
To explore whether our observation might be related to retinal disease, such 
as posterior vitreous detachment (PVD), we retrospectively reviewed all SD-OCT 
images containing the RNFL schisis. Peripapillary vitreoretinal traction syndrome, 
with retinal thickening next to the ONH is associated with PVD.15,16 We therefore 
explored the presence of other retinal diseases by careful scrutiny of all SD-OCT 
B-scans at large magnification.
Longitudinal
When possible, we compared the images during the focal retinoschisis with the 
outcome either before or after the schisis. In the VF, we calculated the mean retinal 
sensitivity (MRS) of all individual points in the corresponding sector, as presented 
on the printout. We used the paired Student’s t-test to evaluate differences be-
tween the MRS of the measurements during and before / after the disturbed area. 
In the HRT, Topographic Change Analysis (HRT-TCA) was used to determine any 
changes in height of the RNFL.
One hundred and eighty-nine eyes of 117 glaucoma patients (66 men, 51 women), 
as well as 182 eyes of 91 healthy subjects (36 men, 55 women) were measured at 
least once, with a maximum follow up time of 34 months. The mean age of the 
healthy subjects was 57 years (SD 13) and of glaucoma patients 69 years (SD 10).
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resulTs
Seven out of 189 glaucomatous eyes showed a transient, localised, peripapillary 
schisis of the RNFL and sometimes of other retinal layers as well. This phenomenon 
was not observed in any of the 182 healthy eyes (p=0.0089, χ²-test). All 7 subjects 
were women. Their mean age was 70.7 years (SD 8.3). The subject and scan charac-
teristics have been presented in Tables 1 & 2.
Table 1 Subject characteristics.
Case Eye Age 
(years)
IOP 
(mmHg)
Severity 
Glaucoma*
Glaucoma 
treatment
Surgical interventions
#1 OD 61.5 14 Moderate None Trabeculectomy (2007)
#2 OD 63.2 15 Advanced None Trabeculectomy (1995)
#3 OD 76.2 12 Mild Dorzolamide/
Timolol; Latanoprost
None
#4 OD 72.8 14 Advanced Dorzolamide/
Timolol; Carteolol
None
#5 OD 61.8 12 Moderate Timolol; Bimatoprost Trabeculectomy (2000)
#6 OD 80.6 21 Mild Timolol YAG PI (1996), Trabeculoplasty (1999)
#7 OS 78.6 12 Mild Timolol YAG PI (1996)
* Mild glaucoma: MD >-6dB; Moderate glaucoma -12dB>MD>-6dB; Advanced glaucoma <-12dB
Abbreviations: IOP: Intra-ocular pressure; YAG PI: yttrium-aluminium-garnet (YAG) laser peripheral 
iridotomy; MD: Mean Deviation (of visual field)
Table 2 Characteristics of SD-OCT and visual field of each case.
Case
 
SD-OCT  VF
Location RNFL schisis Layers involved # abnormal points
#1 Superotemporal (ST) RNFL, GCL 10 (10) (ST)
#2 Superotemporal (ST) RNFL, GCL 7 (10) (ST)
#3 Nasal (N) RNFL, GCL, ONL 1 (4) (N)
#4 Temporal (T+IT) RNFL 17 (19) (T/IT)
#5 Inferotemporal (T+IT) RNFL, GCL, INL 7 (16) (T/IT)
#6 Inferotemporal (IT) RNFL, GCL 8 (13) (IT)
#7 Superotemporal (ST) RNFL 0 (10) (ST)
An abnormal point was an individual point below the 0.5% probability level in either the total or the 
pattern deviation plot. The number of abnormal points (+ total amount of points) were counted per 
sector corresponding with the location of the schisis of the RNFL in SD-OCT.14
Abbreviations: SD-OCT: spectral domain optical coherence tomography; RNFL: retinal nerve fiber 
layer; GCL: ganglion cell layer; ONL: outer nuclear layer; INL: inner nuclear layer; VF: visual field.
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Scan images
The SD-OCT scans of all 7 cases showed an area of schisis of the RNFL. This area 
was well demarcated on the en-face infrared image and it verged on the ONH. 
In all cases, the schisis appeared as a localised, heterogeneous microcystic mass 
within the RNFL and sometimes also partially on top of it (cases 4 and 5). In most 
cases, other layers under the RNFL were involved as well, such as the ganglion cell 
layer (cases 1, 4, 6), or even deeper retinal layers, like the inner and outer nuclear 
layer (cases 3 and 5). None of the SD-OCT scans of these cases showed any signs 
of other ONH- or retinal abnormalities, such as posterior vitreous detachment or 
a macular pucker. An overview with images of three cases is presented in Figure 1.
Outcome other imaging devices
No other imaging device captured this localised retinoschisis as clearly as the SD-
OCT did. In 6 cases, the visual field showed a glaucomatous defect in the sectors 
corresponding with the location of the schisis in the SD-OCT images. In the case 
=
Case 5
=
=
Case 2
<
Case 6
<
>
>
Figure 1 IR (right) and SD-OCT images of 3 cases, representing cases with measurements before (<) 
and during (=) the retinoschisis (Case 2); and representing cases with measurements during and after 
(>) the retinoschisis (Case 5). Case 6 was the only case imaged before (<), during (=) and after (>) the 
presence of the retinoschisis. The detail inside the red boxes represents the retinoschisis. Between 
the red arrows in the IR fundus images is the area of the focal retinoschisis.
Abbreviations: IR: infrared image; SD-OCT: spectral domain optical coherence tomography
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without a glaucomatous visual field defect in the corresponding sector (case 7), 
the thickening was located in a very small wedge defect. In none of the cases was 
the RNFL schisis detectable by SLP (GDx); its image only showed a localised RNFL 
wedge at the same location. In three cases, the retinoschisis was displayed also by 
SLT (HRT-3D), presented as a slightly elevated surface in the three-dimensional im-
age. In one case, we performed fluorescence angiography during the retinoschisis 
to seek for any signs of a pathophysiological mechanism. Besides some atheroscle-
rotic arteries, the angiogram showed no pathological patterns, such as leakage or 
other signs of inflammation.
The disagreements between the various imaging techniques in the ability to 
capture the transient, focal retinoschisis have been illustrated by Figure 2.
Outcome over time
All 7 subjects were measured at least four times with SD-OCT at 6-monthly inter-
vals. In case 6 we saw that the retinoschisis was present at the fourth measurement 
and that it had disappeared after 13 months. In cases 4 and 5, the retinoschisis 
Color fundus photograph
SD-OCT image SD-OCT thickness map Visual field
Fluorescence angiograph
GDx RNFL map
HRT reflectance map HRT topography map
Figure 2 SD-OCT, Scanning Laser Polarimetry (GDx), visual field, color fundus photograph, fluores-
cence angiograph and Scanning Laser Tomography (HRT) images during the presence of the focal 
retinoschisis in Case 6. The SD-OCT image shows the retinoschisis inferotemporally (see thickness 
map). The thickness map shows the total retinal thickness. The GDx shows no increased RNFL thick-
ness. The color fundus photograph as well as the fluorescein angiography show no clear signs of the 
retinoschisis, except for atherosclerotic arteries inferiorly to the ONH. The HRT shows a darker area 
at the thickened location in the reflectance map, as well as a slight increased height in the topogra-
phy map.
Abbreviations: SD-OCT: Spectral Domain Optical Coherence Tomography; RNFL: retinal nerve fiber 
layer.
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disappeared, and in cases 2 & 3, the schisis occurred within the time frame of these 
measurements. In cases 1 and 7, we observed the retinoschisis in all measurements, 
suggesting it can last for at least 27 months. The images taken with and without the 
schisis, in the same location, have been presented in Figure 1.
Of the 5 eyes imaged both with and without the presence of retinoschisis, 4 
eyes were imaged with other devices as well. As presented in Table 3, the defect 
in the visual field, expressed by the MRS, appeared to be worse during the time 
of retinoschisis. In 3 of these 4 eyes, the MRS decreased by at least 2.5 dB during 
the retinoschisis, statistically non-significantly however. In none of these 4 eyes did 
the GDx and HRT-TCA show any change in height. The HRT-3D image did reveal a 
focally elevated surface when the schisis was present.
dIsCussIon
This study presents a focal schisis of the retinal nerve fiber layer (RNFL) and 
sometimes deeper retinal layers in glaucomatous eyes. None of the healthy eyes 
showed this phenomenon. In all cases, the retinoschisis was located in an area of a 
pre-existing glaucomatous RNFL defect, which suggests that this phenomenon is 
associated with glaucomatous wedge defects of the RNFL.
Several recent studies presented cases with peripapillary retinoschisis, imaged 
with SD-OCT.8-13 All studies showed a relation of the retinoschisis with the presence 
of glaucoma. We also observed the retinoschisis in glaucomatous eyes only, all 
verging on a glaucomatous (wedge) defect. Kahook et al.11 presented two cases 
with retinal schisis cavities in the presence of narrow occludable angles and in-
creased intraocular pressure, suggesting a tight relation, which has been confirmed 
Table 3 Measurement characteristics of visual field of four cases of measurements with and without 
the focal retinoschisis.
Case Visual field
MRS during 
retinoschisis
Moment without 
retinoschisis
MRS without 
retinoschisis
Difference p-value*
#3 24.3 [SD 5.1] < 21.3 [SD 3.3] 3.0 0.19
#4 5.5 [SD 9.1] > 8.2 [SD 10.9] -2.7 0.04
#5 17.6 [SD 9.4] > 20.1 [SD 9.5] -2.5 0.14
#6 17.3 [SD 7.0] < & > 20.9 [SD 6.6] -3.5 0.04
The MRS was calculated in the sector corresponding with the location of the RNFL schisis on spec-
tral-domain optical coherence tomography.14 The moment without retinoschisis is presented as be-
fore (<) or after (>) the retinoschisis.
* paired Student’s t-test
Abbreviations: MRS: mean retinal sensitivity; RNFL: retinal nerve fiber layer
102
Transient p
erip
ap
illary retino
schisis in g
lauco
m
ato
us eyes
7
by Lee et al.12 Our data did not confirm this finding, but we found the retinoschisis 
in open angles and with low intraocular pressures as well, suggesting a different 
pathophysiology. Because they followed a large population for several years, Lee 
et al. were able to observe spontaneous resolution of the retinoschisis.12 We also 
observed that the retinoschisis appeared and disappeared with various time spans 
between eyes, ranging from less than six months up to over 27 months.
None of the previously mentioned studies adopted other techniques commonly 
used for monitoring glaucoma to investigate their ability to detect this retinos-
chisis or to relate it to glaucomatous loss or potential progression. We followed 
all participants longitudinally with visual field testing, SLP, SLT and SD-OCT. All 
these techniques measured a glaucomatous (wedge) defect at the location of 
the retinoschisis. Interestingly, the schisis itself of the RNFL and sometimes other 
deeper retinal layers could hardly be detected by any of the other imaging devices. 
SLP (GDx) did not detect this schisis at all. This is not very surprising, because the 
GDx measures retardation. Without any change to the number of nerve fibers and 
without any substantial change in their course, we would not have expected any 
changes in retardation. The apparent accumulation of fluid within the schisis area 
would not have led to a change in retardation, similar to the lack of change in case 
of disc edema.17 SLT (HRT) did capture the thickening in the three-dimensional 
surface display, but it failed to detect any schisis by the HRT parameters.
In the eyes in which the retinoschisis appeared between measurements or 
disappeared over time, a corresponding difference in RNFL-thickness on SD-OCT 
was observed. The HRT and GDx did not appear to measure any differences in 
RNFL thickness between measurements prior to or after the RNFL schisis nor dur-
ing its presence. The visual field, however, showed a, statistically not significant, 
decreased mean retinal sensitivity (MRS) of at least 2.5dB during the retinoschisis 
at the exact location corresponding with the schisis14, compared to the visual field 
before or after the retinoschisis. This suggests a temporary decreased function 
due to the retinoschisis, fortunately not leading to permanent progression of the 
glaucomatous defect.
The pathophysiological mechanism of this schisis is unclear. Most likely, the 
schisis contains fluid, since its reflectivity is lower than the surrounding tissues and 
it absorbs or scatters part of the incident light. The origin of the fluid remains 
unclear. Potentially, thickening and fluid accumulation might be characteristic 
of inflammation. The absence of other signs of inflammation, including the fully 
normal fluorescence angiography in our study, suggests another cause. As sug-
gested by others8,11,12, the fluid might be of vitreous origin. The fluid might enter 
the RNFL through microscopic interconnections, leading to the schisis. Kahook et 
al. hypothesize that pressure peaks lead to changes in axial length, which might 
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lead to vitreous traction.11 Whenever the vitreous detaches from the inner limiting 
membrane, this might lead to peripapillary vitreoretinal traction syndrome with 
retinal thickening next to the ONH.15,16,18 Our SD-OCT scans, combined with retro-
spective medical chart search for any PVD observations, showed no signs of other 
ONH- or retinal abnormalities potentially causing thickening and edema inside the 
retina. Since all cases differed somewhat in their treatment, we do not think the 
retinoschisis was therapy related.
The focal retinoschisis always verged on the ONH, suggesting it follows the pat-
tern of loss of nerve fibers. In addition, the RNFL schisis seems to follow the nerve 
fibers into the lamina cribrosa, suggesting that the fluid might enter the RNFL from 
the subarachnoidal space through the lamina cribrosa along the tiny canals created 
by the pathological absence of previously present nerve fibers. Recently, Lee et al. 
strengthened this hypothesis by presenting the relationship between retinoschisis 
and damage to the lamina cribrosa.13 They found that the location of the lamina 
cribrosa abnormalities, found on OCT with enhanced depth imaging, appeared 
to be associated with the involved retinal layers. Lee et al. related this hypothesis 
to the presence of an optic pit, which was found in 36% of their cases.12 The eyes 
in our study did not show any optic pits. Interestingly, cerebrospinal fluid contains 
proteins, which in SD-OCT potentially lead to shadowing effects, causing relatively 
lower reflectivity of the retinal layers underneath. This matches our findings such as 
illustrated in Figure 1, strengthening this hypothesis. Whether proteins would re-
tain between or in the retinal layers after the resolution of the fluid remains unclear. 
Our data did not show any visible signs of differences in reflectivity of the retinal 
layer at the location of the former schisis and its surrounding area, suggesting that 
the proteins dissolve completely.
Our study was subject to some limitations. First, this study was based on a review 
of images obtained from a large prospective longitudinal study into glaucoma 
imaging, which was not specifically designed for investigating the clinical course of 
retinoschisis. Second, the sample size was small. We therefore think that the only 
remarkable finding in the patient characteristics, i.e. that all subjects that showed 
the retinoschisis were women, is probably coincidental and due to this small sample 
size. On the other hand, a large group of subjects with glaucoma were included 
in our long term follow up study on glaucoma imaging, while only few showed 
the retinoschisis. In fact, only about 4% of the 189 eyes measured for many years 
showed the retinoschisis. Further longitudinal follow-up of a larger population is 
necessary to address the exact course of the retinoschisis and its potential relation 
to glaucomatous progression.
In conclusion, our data suggest that transient, localised, peripapillary schisis of 
the RNFL, and sometimes other deeper retinal layers, is associated with glauco-
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matous RNFL wedge defects. Of all techniques used to monitor glaucoma in daily 
practice, the retinoschisis was best observed with SD-OCT. The visual fi eld showed 
a temporary focally decreased sensitivity during the retinoschisis. We found no 
evidence that the retinoschisis predicts glaucomatous progression.
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absTraCT
Purpose. To demonstrate the effect of glaucoma on the optical attenuation coef-
ficient of the retinal nerve fiber layer (RNFL) in Spectral Domain Optical Coherence 
Tomography (SD-OCT) images.
Methods. We analyzed images of the peripapillary areas in 10 healthy and 30 glau-
comatous eyes (mild, moderate and advanced glaucoma, 10 eyes each), scanned 
with the Spectralis OCT (Heidelberg Engineering GmbH, Dossenheim, Germany). 
To calculate the RNFL attenuation coefficient (µatt), determined by the scattering 
properties of the RNFL, we used a model that normalized the reflectivity of the 
RNFL by the retinal pigment epithelium. The analysis was performed at 4 preset 
locations around the optic nerve head (ONH) (i.e. temporally, superiorly, nasally 
and inferiorly) and on averages per eye. To assess the structure-function relation-
ship, we correlated the µatt to the Mean Deviation (MD) in standard automated 
perimetry (SAP).
Results. The µatt of the RNFL decreased up to 40% with increasing disease severity, 
on average as well as in each location around the ONH (Jonckheere-Terpstra test, 
P < 0.001 in all tests). The µatt of the RNFL depended significantly on the location 
around the ONH in all eyes (Kruskal-Wallis test, P<0.001) and was lowest nasally 
from the ONH. The µatt correlated significantly with the MD in SAP (R2 = 0.337, 
p<0.001).
Conclusion. The measurements clearly demonstrated that the µatt of the RNFL 
decreased with increasing disease severity. The RNFL attenuation coefficient may 
serve as a new method to quantify glaucoma in SD-OCT images.
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InTroduCTIon
In glaucoma, retinal nerve fibers are damaged and lost, leading to thinning of 
the retinal nerve fiber layer (RNFL)1, 2 . Optical coherence tomography (OCT), a 
technique used e.g. for in vivo retinal imaging, can measure the thickness of retinal 
layers, such as the RNFL. Since its development3, 4 for ophthalmology, this technol-
ogy has been predominantly used for imaging the macula and macular diseases, 
and, to a lesser extent, glaucoma. Time Domain OCT (TD-OCT) yielded a gradually 
improving reproducibility of measurements over the past decade5-9. Nevertheless, 
it never exceeded the diagnostic capabilities of other structural measurement 
techniques for glaucoma, such as scanning laser polarimetry (SLP) and confocal 
scanning laser ophthalmoscopy (CSLO)9-12 . Since the recent development of Spec-
tral Domain Optical Coherence Tomography (SD-OCT)13-16 , OCT is increasingly 
used in glaucoma assessment because of its high image resolution, high reproduc-
ibility of measurements17-23 and diagnostic accuracy24-26 .
The local signal strength of the OCT is used to measure thickness of retinal lay-
ers. Optical scattering properties of each retinal layer are closely related to the 
tissue properties. Pons et al.27 reported a decreased reflectivity of the RNFL in 
glaucoma measured with TD-OCT. In a recent study, we confirmed the diminished 
reflectivity of the RNFL in glaucomatous eyes compared to healthy eyes in SD-OCT 
images [Van der Schoot, IOVS, 2010, 51, ARVO E-Abstract, 212]. Even focal defects 
are detected by this method (Vermeer, IOVS, 2011, 52, ARVO E-abstract, 3666). 
Figure 1 illustrates the difference in reflectivity of the RNFL between a healthy and 
a glaucomatous eye. These findings suggest that glaucomatous damage is not 
only reflected by the thickness of the RNFL, but also by changes in its optical scat-
tering properties. The latter may potentially lead to a new method to diagnose or 
follow glaucoma.
 
Figure 1 SD-OCT image of a healthy eye (left) and of an advanced glaucomatous eye (right). The 
two coloured areas represent the manual segmentation of the areas of the RNFL (blue) and RPE 
(purple), used for analysis. Note the reduced brightness of the retinal nerve fiber layer (RNFL) in the 
glaucomatous eye compared to the healthy eye, representing the diminished RNFL reflectivity in the 
glaucomatous eye.
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To determine the optical scattering properties of a retinal layer, it is not sufficient 
to measure its reflectivity. The measured reflectivity of a layer is sensitive to e.g., 
media opacities and light collection geometry. Therefore, a relative measurement 
is necessary to extract quantitative scattering properties from OCT images. In 
this article we present a method to quantify the attenuation coefficient (µatt) of 
the RNFL in SD-OCT images, by taking the scattering properties of the retinal 
pigment epithelium (RPE) as a reference. To investigate the µatt of the RNFL as 
a clinical diagnostic parameter, we measured the µatt of the RNFL in healthy and 
glaucomatous eyes.
PaTIenTs and MeThods
Participants
Datasets of 10 healthy subjects and 30 subjects with glaucoma were randomly 
selected from a larger population, participating in a longitudinal prospective 
follow-up study into glaucoma imaging. The selection of the 30 glaucomatous sub-
jects was based on the severity of their glaucoma per eye, stratified by the Mean 
Deviation (MD) of the visual field test (determined with the standard 24-2 W/W 
SITA test programme of the Humphrey Field Analyzer, Carl Zeiss Meditec, Dos-
senheim, Germany). The severity of glaucoma was defined as an MD between 0 dB 
and –6 dB, between –6 dB and –12 dB and worse than –12 dB, for mild, moderate 
and advanced glaucoma, respectively. Of each group, 10 eyes of different subjects 
were randomly selected.
For inclusion, a healthy subject needed to have a normal visual field and an 
intraocular pressure below 22 mmHg. A normal visual field had, by definition, a 
Glaucoma Hemifield Test within normal limits and an MD and PSD within the 95% 
confidence intervals. Visual fields were considered as glaucomatous if they had at 
least 2 of the following on at least 2 separate occasions: a PSD significant at the 5% 
probability level, a Glaucoma Hemifield Test outside normal limits and a cluster of 
more than 2 points below the 5% probability level or 1 individual point below the 
1% probability level. All patients were recruited from the population treated for 
glaucoma at the Rotterdam Eye Hospital.
Subjects were excluded from participation in the presence of any coexisting ocu-
lar or systemic disease known to possibly affect the visual field (e.g. diabetes mel-
litus), a history of intraocular surgery (except for uncomplicated cataract surgery or 
glaucoma surgery in glaucoma patients), uncontrollable arterial hypertension, and 
secondary glaucoma in case of glaucoma.
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All participants had a best-corrected Snellen visual acuity of at least 20/40 in 
both eyes, a spherical equivalent refractive error between -10.0D and +5.0D, and 
had unremarkable findings upon slit-lamp examination, including open angles on 
gonioscopy.
The methods and procedures used in this study adhered to the Declaration 
of Helsinki. Informed consent was obtained from all participants. This study was 
approved by the Medical Ethics Committee of the Erasmus Medical Centre, Rot-
terdam, The Netherlands.
All participants were scanned once with the Spectralis OCT (Heidelberg Engi-
neering, Dossenheim, Germany) between January and September 2009. The optic 
disc and peripapillary area were scanned by means of a volume scan of 20 by 20 
degrees. This scan contained 193 B-scans, each consisting of 512 A-scans. Each B-
scan was an average of 5 scans on the same location (made possible by the built-in 
eye-tracking system on the Spectralis OCT with ART value 5). The lateral distance 
between adjacent B-scans was 30 µm. To minimize the decrease in sensitivity as a 
function of depth, all retinal cross sections were placed in the upper one third of 
the scan depth. A volume scan was excluded, if the proprietary overall quality score 
provided by the Spectralis was below 15 dB or if the volume scan was incomplete 
due to the built-in maximum acquisition time of 300 seconds.
Image Processing and Model
We used the exported raw data of optic nerve head (ONH) scans for all analyses. To 
determine the reflectivity, we exported the raw data which represents the measured 
intensity on a linear scale between 0 and 1. The device displays these intensities in 
a grayscale image after applying the following formula: Y=4√X; where X represents 
the raw data values; Y=0 represents no reflectivity and Y=1 maximum reflectivity28 .
The model we developed, is based on two different scattering layers: the RNFL 
and the RPE. Assuming that the backscatter properties of the RPE are constant, 
we used it to normalize the RNFL OCT signal. The model can be summarized as 
follows: The amount of light that is backscattered from the RNFL is proportional 
to the incident intensity and the amount by which the incident beam on the eye is 
attenuated due to scattering. The incident light that is not scattered by the RNFL 
propagates to the RPE, and is partially backscattered by the RPE. The ratio of total 
light backscattered by the RNFL (RNFL reflectivity) and the RPE (RPE reflectivity) is 
now related to the µatt of the RNFL according to the following formula:
d
R
att 
¹¸
·
©¨
§ 
 
2
1
3.2
log
P , 
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in which µatt represents the attenuation coefficient in mm-1, R is the ratio between 
the reflectivity of the RNFL and RPE, and d is the thickness of the RNFL in mm. The 
model is derived in the Appendix.
The analysis of the µatt was performed in all 4 quadrants around the optic nerve 
head (ONH) at fixed locations. The centre of the ONH was manually selected, tak-
ing the border of the RPE as a reference. From this centre of the ONH, the areas 
of interest were selected 1.3 mm superiorly, inferiorly, temporally and nasally. To 
correct for any failed B-scans, the best out of 3 B-scans closest to the selected 
distance was selected for analysis. Per B-scan, we selected an area for analysis of 
20 pixels wide. If the selected area of 20 pixels contained any blood vessels, the 
20 pixels wide window was shifted along the B-scan toward an area without blood 
vessels, to avoid any scatter caused by the blood vessel. We determined the µatt in 
all 4 peripapillary locations separately and calculated the mean µatt per patient by 
averaging µatt of these 4 locations. The error of the mean µatt was calculated over 
the patient population.
To obtain the reflectivity of each retinal layer separately, the layers were manually 
segmented and color coded by a manual segmentation tool, called ITKSNAP29. 
The color coding was manually performed by a trained physician. The reflectivity 
of the RNFL and the RPE were used for analysis. An example of this color coding is 
presented in Figure 1.
Of the 3 selected B-scans (one superiorly, one inferiorly and one running from 
nasally to temporally to the ONH, containing the nasal and the temporal 20 pixel 
wide area of interest), the quality scores (as given by the device) were reported, 
ranging from 0 dB to 40 dB.
To correlate the measure of structure (µatt) with a measure of function, we noted 
the MD of the visual field test, which was performed by all participants in the same 
visit as the Spectralis measurement.
Statistics
We used an analysis of Generalized Estimating Equations (GEE) to test for differ-
ences in the demographics. The Jonckheere-Terpstra test for trend was used for 
comparison between the µatt of healthy eyes and of the 3 groups of glaucomatous 
eyes and to test for a trend in the µatt between the various locations around the 
ONH. We used the Kruskall-Wallis test to test for the presence of an effect of loca-
tion on µatt. We calculated the coefficient of determination (R2) of exponential re-
gression analysis between MD and µatt. A significance level of 0.05 was considered 
to be statistically significant.
113
Lig
ht attenuatio
n in g
lauco
m
ato
us R
N
FL o
n SD
-O
C
T
8
resulTs
Between the 4 groups of randomly selected subjects, there were no statistically 
significant differences in age and scan quality (Table 1). The MD showed a sta-
tistically significant difference between the 4 groups, decreasing with increasing 
disease severity (Table 1). No patients were excluded because of bad scan quality 
(<15dB) or incomplete scans. Examples of an SD-OCT image of a healthy eye and 
of a glaucomatous eye are shown in Figure 1.
The mean attenuation coefficient (µatt) of the healthy and the mild, moderate and 
advanced glaucomatous eyes, as well as for each location, have been presented in 
table 2. The average µatt of the RNFL showed a statistically significant trend for de-
creasing µatt with increasing disease severity (Jonckheere-Terpstra test, P < 0.001). 
Figure 2 shows the trend of decreasing average µatt of healthy and glaucomatous 
eyes, increasing in severity.
The location significantly affected the µatt of the RNFL in all 4 groups (Kruskal-
Wallis test, P<0.001). In these eyes, the µatt of the RNFL was lower nasally than in the 
other locations. All locations showed a statistically significant trend for decreasing 
µatt with increasing disease severity (Jonckheere-Terpstra test, P < 0.001 for tempo-
ral, superior, nasal and inferior). These findings are illustrated by Figure 3.
Table 1 Patient Demographics and Scan Quality
 Healthy Mild glaucoma Moderate 
glaucoma
Advanced 
glaucoma
p-value
Mean age (years) 63.7 [SD 9.9] 65.3 [SD 1.4] 66.1 [SD 7.1] 71.8 [SD 9.3] 0.18
MD (dB) 0.15 [SD 1.10] -2.80 [SD 1.39] -9.05 [SD 3.64] -17.65 [SD 4.31] <0.001
Scan quality (dB) 26.5 [SD 3.6] 24.0 [SD 3.9] 24.4 [SD 2.9] 24.5 [SD 3.8] 0.2
Analysis of Generalized Estimating Equations for differences between age, Mean Deviation (MD) 
and scan quality in healthy, mild, moderate and advanced glaucomatous eyes.
Table 2 Mean (± standard error) Attenuation Coefficient µatt in healthy and glaucomatous eyes [mm-1]
 
 
Attenuation Coefficient of the Retinal Nerve Fiber Layer
Average Temporal Superior Nasal Inferior
Healthy 4.78 ± 0.27 5.25 ± 0.59 5.31 ± 0.53 3.60 ± 0.53 4.96 ± 0.42
Mild Glaucoma 4.09 ± 0.28 4.72 ± 0.72 4.41 ± 0.47 2.73 ± 0.46 4.51 ± 0.38
Moderate Glaucoma 3.14 ± 0.25 3.33 ± 0.49 3.99 ± 0.49 1.74 ± 0.20 3.51 ± 0.46
Advanced Glaucoma 2.93 ± 0.24 3.54 ± 0.54 3.67 ± 0.46 2.02 ± 0.26 2.48 ± 0.42
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Diagnosis
Advanced 
Glaucoma
Moderate 
Glaucoma
Mild GlaucomaHealthy
µ-
at
t (
1/
m
m
)
6,0
5,0
4,0
3,0
2,0
Error Bars: +/- 1. SE
Page 1
Figure 2 Box plot of the average attenuation coefficient µatt [mm-1] in healthy and glaucomatous 
eyes.
Figure 3 Plot presenting the trend of decreasing attenuation coefficient µatt (mm-1) with increasing 
disease severity for all locations separately. Note the difference in µatt between the nasal and the 
other locations.
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We also found a significant relationship between MD and µatt (R2 = 0.337, p<0.001). 
The plot of this correlation is presented in Figure 4.
dIsCussIon
The attenuation coefficient (µatt) of the RNFL decreased with increasing disease 
severity in SD-OCT images of healthy and glaucomatous eyes. We created a model 
to quantify the optical scattering properties from OCT data by calculating µatt. 
The model was based on the reflectivity of the RNFL and the RPE, on interaction 
between light and the tissue and on the thickness of the RNFL. This novel analysis 
confirms earlier conclusions, i.e. that the optical scattering properties of the RNFL 
change in glaucoma27 [Van der Schoot, IOVS, 2010, 51, ARVO E-Abstract, 212] . 
In our current study we looked at the attenuation coefficient, because it is based 
on relative measurements of the reflectivity. Absolute measurements of reflectivity 
might be affected by a number of factors, such as the particular alignment of the 
OCT beam on the cornea, and media opacities. Relative measurements are less 
sensitive to these factors and thus provide a more reliable measure of change 
related to pathological processes in glaucoma.
MD (dB)
0,00-10,00-20,00-30,00
µ-
at
t (
1/
m
m
)
8,0
7,0
6,0
5,0
4,0
3,0
2,0
1,0
Page 1
Figure 4 Plot presenting the correlation between the attenuation coefficient µatt (mm-1) and the 
Mean Deviation MD (dB), from the visual field test. The coefficient of determination (R2) of exponen-
tial regression analysis between MD and µatt is 0.337 (P < 0.001).
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The model we developed incorporated the backscatter signal of the RNFL 
and the RPE and not of the layers in between. These layers have a relatively low 
backscatter signal, compared to the RNFL and RPE30 , and they attenuate only a 
relatively small part of the incident light. Moreover, the attenuation of these layers 
is uncorrelated with disease severity and was therefore not incorporated in our 
model. We also assumed the backscatter properties of the RPE to be constant. 
This assumption does not hold in case of peripapillary atrophy (PPA). In glaucoma, 
the RPE near the ONH can be affected by PPA, an important cause of irregular RPE 
around the ONH. PPA can be divided into 2 zones, the alpha and beta zone. The 
alpha zone is characterized by pigmentary irregularities in the RPE, while the beta 
zone, which is nearest to the ONH, correlates with a complete loss of RPE cells31 . 
The alpha zone is nearest to the location of our analyses, which was 1.3 mm from 
the centre of the ONH. It is sometimes difficult to exactly delineate the peripheral 
border of alpha zone PPA. In retrospect, only 1.9% of the regions of analysis of 
our included eyes potentially contained some alpha zone PPA. Therefore, we feel 
confident that the PPA did not significantly affect our dataset.
We hypothesize that µatt indirectly measures the nerve fiber density of the RNFL. 
Evidently, there is loss of nerve fibers due to glaucoma2 . In a histology study, 
Quigley et al.1 measured a decrease of the fiber density in glaucomatous eyes 
compared to healthy eyes. A structural change due to glaucoma, i.e. the decreased 
density of the nerve fibers, is also thought to be associated with a decrease in 
birefringence of the RNFL32, 33 . A decreased nerve fiber density will also have its 
effect on the optical scattering properties of the RNFL. The denser the tissue is, 
the more the incident light is attenuated by the RNFL. We found that the µatt of the 
RNFL diminished with increasing disease severity. A reduction of µatt could be an 
early sign of glaucomatous damage. This hypothesis is supported by the findings 
of Huang and others. Firstly, they found that 50% of the RNFL reflectance is caused 
by microtubules34 and secondly they found a change in reflectance of the RNFL 
to precede thinning of the RNFL35 . Future studies are needed to elucidate the 
relation between µatt, reflectance, and glaucomatous damage.
The location significantly affected the µatt of the RNFL. µatt was lower nasally from 
the ONH, compared to the other locations (temporally, superiorly and inferiorly) 
in both healthy and in glaucomatous eyes. These differences in µatt appear to be 
unrelated to glaucoma, because they occurred in both glaucomatous and healthy 
eyes. The difference between the retina nasally from the ONH and the other loca-
tions, is that the RNFL is usually thinner nasally. More importantly, the incident 
light being reflected by the RNFL nasally is probably less compared to the other 
locations because of a different angle of this part of the retina. The nasal side 
of the ONH is more towards the periphery, leading to a higher retinal curvature 
117
Lig
ht attenuatio
n in g
lauco
m
ato
us R
N
FL o
n SD
-O
C
T
8
perpendicular on the light beam. The less perpendicular the RNFL is to the light 
beam and consequently, the larger the scan angle is, the smaller the refl ectance 
of the cylindrical nerve fi bers will be. 36 This might explain the lower µatt nasally 
compared to the other locations.
We also assessed a structure-function relationship by correlating µatt to the MD. 
In previously published studies, in which the average RNFL thickness was used as 
a structural measure, and an index of visual fi elds as the functional measure, the 
structure-function relationship was generally quite weak and variable (R2 from 0.08 
to 0.5537-40 ). In our current study, the structure-function relationship between µatt 
and MD showed a correlation well within the same range (R2 = 0.337). Compared 
to earlier structure-function studies37-40 , this result is promising, since our model 
is a fi rst attempt of characterizing RNFL scattering properties in SD-OCT images. 
Further development in modeling the relationship between the µatt and an index 
of visual fi elds is needed to explore the use of µatt as a measure for structure in 
characterizing a structure-function relationship.
To our knowledge, SD-OCT currently does not consistently outperform several 
other available techniques in their diagnostic accuracy, such as SLP and CSLO9-12 
. With every available imaging technique, it is notably diffi cult to detect early 
glaucoma, because of the large biological variation between healthy eyes and the 
inherent overlap with glaucomatous eyes. We have currently created a model for 
SD-OCT to quantify the attenuation of light, which is related to the optical scatter-
ing properties of the RNFL. With our method, we found a clear effect of glaucoma 
on the µatt of the RNFL. The correlation of µatt with standard automated perimetry 
(SAP) is comparable to that of SLP and CSLO with SAP37-40 . We speculate that the 
reduced µatt of the RNFL in SD-OCT images in glaucomatous eyes might serve as 
a discriminating feature for structural changes. Future studies are needed to clarify 
the role of the µatt of the RNFL in diagnosing and following glaucoma with SD-OCT, 
potentially leading to a new method to quantify glaucoma in SD-OCT images.
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aPPendIx - Model
The proposed model is based on two different scattering layers: the RNFL and 
the RPE. The former is the layer of interest, while the latter will serve as an internal 
calibration layer. These layers are also the two most scattering layers in the retina. 
Other, weakly scattering retinal layers are not included. Assuming constant RPE 
backscatter properties, this layer is used to normalize the OCT signal from the 
RNFL. First, a model of the interaction between light and tissue is described. This 
model is then applied to the RNFL and the RPE, producing a method to determine 
the RNFL attenuation coefficient.
Attenuation and scattering of a homogeneous layer
The incoming beam, with a power of I0 when it arrives at the front surface of the 
tissue, is attenuated by the tissue according to  xI
dx
dI
att  P . 
The power of the beam at depth x is then given by I(x) = I0e-µx, where µatt is the 
attenuation coefficient of the tissue. Combining these equations produces the at-
tenuation of the light at depth x : µatt · I(x) = µatt · I0e-µx . A fraction of the attenuated 
light, given by α, is backscattered. Before reaching the detector, this light is again 
attenuated by the tissue. The power of the light at the detector that was backscat-
tered at depth x is then given by α · µatt · I0e-2µx. Integrating over a depth range d 
results in the total power of the backscattered signal at the detector
 dd
x
x
att e
I
dxeIT PP
DPD 2
0
02
0 12

 
   ³ .      (1) 
RNFL
The RNFL is the first retinal layer that the incident light beam interacts with. The 
total backscattered signal for the RNFL is given by
 RNFLRNFLdRNFLRNFL eIT PD 20 12  ,       (3) 
RPE
Light that reaches the RPE is first attenuated by the RNFL. After interacting with the 
RPE, the backscattered light is again attenuated by the RNFL. The total backscat-
tered signal for the RPE is therefore given by
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 RNFLRNFLRPERPE ddRPERPE eeIT PPD 220 12   .      (5) 
Deriving µ
Calculating the ratio of the total OCT signal of the RNFL and the RPE yields
RNFL
RPE
T
R
T
  
 
  RNFLRNFLRPERPE
RNFLRNFL
ddRPE
dRNFL
ee
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e
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Assuming that αRNFL and αRPE are constant, and that the attenuation of the RPE is 
constant (i.e., µRPE and dRPE are constant), this equation reduces to
 12  datteR PE .          (8) 
Solving this equation for µatt results in
 
d
R
att 2
1/log  EP .         (9) 
Calculating β
In equation 9, µ can be calculated if R, d and β are known. Both R and d can be 
determined from a segmented OCT scan. Given that β is a constant in our model, 
it may be estimated from the data. For estimating β, equation 8 was used. The 
data set contained R and d determined from OCT data of healthy eyes, and µ and 
β were fitted to the model by minimizing the error
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The result is shown in the Figure and the optimal fit was found for β = 2.3 (and µatt 
= 4.6 mm-1).
Figure Scatter plot of the ratio (R) between the reflectivity of the RNFL and RPE 
against the RNFL thickness (d) for healthy eyes.
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General dIsCussIon
In this thesis we investigated various techniques used for diagnosing and monitor-
ing glaucoma. The first difficulty in this matter is defining glaucoma. Glaucoma is 
defined as ‘a heterogeneous group of progressive optic neuropathies characterised 
by an accelerated degeneration of retinal ganglion cells (RGCs) and their axons, 
resulting in a typical appearance of the optic nerve head (ONH) and a matching 
pattern of irreversible visual field loss’.1-3
Judging the optic nerve head
In this definition of glaucoma, the terms ‘heterogeneous’ group and ‘typical ap-
pearance’ of the ONH both lead to a mystification of glaucoma. What is a typical 
appearance of the ONH? Apparently, this is one of the hardest aspects an oph-
thalmologist encounters in glaucoma care. Several studies described how hard it 
is to distinguish a healthy ONH from a glaucomatous one.4-10 In Chapter 5 & 6 we 
describe two different aspects of judging the ONH. In daily glaucoma care, an 
ophthalmologist often needs to correlate an ONH he/she judges by the slitlamp, 
with a corresponding visual field. Based on this information, plus the intraocular 
pressure (IOP), the ophthalmologist decides to start therapy or to alter or continue 
the current therapy. In the ESAFAT (Chapter 5), a trial across Europe in matching 
stereoscopic optic disc photographs to its corresponding visual fields of varying 
severity, we found that European ophthalmologists tended to overestimate the 
visual field damage. In Chapter 6, we describe how hard it is to find progression 
solely based on the appearance of the ONH. There was poor agreement between 
eyecare professionals judging an ONH as progressing and progression based on 
visual fields. Apparently, in judging the ONH as having glaucoma or as progressing 
by glaucoma, this ‘typical’ appearance of the ONH does not seem to be so typical 
for an ophthalmologist.
Functional loss
If we, as humans, have so much difficulty in judging ONHs, how good are the 
commercially available structural and functional tests in diagnosing and monitor-
ing glaucoma? To date, there is still no clinically applicable technique that mea-
sures the exact nature of the disease (the death of the RGCs and their axons). 
All techniques developed in the past decades indirectly measure the functional 
and structural loss. The function of the eye is determined by measuring the visual 
field by perimetry. Several types of perimetry have been developed to measure 
the functional glaucomatous loss. Standard automated perimetry is the visual field 
testing used most often and it is currently seen as the gold standard in measuring 
128
G
eneral D
iscussio
n &
 Future Persp
ectives
9
functional glaucomatous loss. Other types of perimetry, such as frequency-dou-
bling technique (FDT) or short wavelength automated perimetry (SWAP), currently 
play a minor role in the daily management of glaucoma. Despite the many years 
of SWAP development, we found that it does not outperform SAP in monitoring 
ocular hypertension and detecting conversion to glaucoma (Chapter 2). Our study 
shows conflicting results compared to earlier studies.11-15 We therefore think that 
early glaucomatous damage is idiosyncratic, and may become first apparent in one 
of different pathways, sometimes appearing first in SWAP and sometimes first in 
SAP. Then, no specific perimetric test can be the gold standard in detecting early 
glaucoma. Fortunately, these conflicting results of our and other trials lead to a 
general advice of, for instance, the European Glaucoma Society to initially perform 
SAP, whereas other types of visual field testing have insufficient evidence to offer 
any advantage over SAP.1
Structural loss
Other techniques developed for measuring glaucoma are based on measuring the 
structural glaucomatous loss by assessing the optic nerve head (ONH) and the 
loss of RGCs and their axons, leading to the typical cupping of the ONH and the 
subsequent loss or thinning of the retinal nerve fiber layer (RNFL). These structural 
changes are currently measured by several imaging techniques, such as optical 
coherence tomography (OCT), confocal scanning laser ophthalmoscopy (CSLO) 
and scanning laser polarimetry (SLP). OCT is in an ongoing promising develop-
ment, whereas CSLO and SLP are currently the two structural techniques that have 
(almost) reached the end of their development. Both techniques yield a diagnostic 
accuracy of more than 90% and 86% for SLP and CSLO respectively.7;16-20 It there-
fore exceeds the ability of ophthalmologists to judge an ONH, with a diagnostic 
accuracy of 80.5%.8 Currently, most studies conclude a poor agreement between 
structure and function21-27 instead of one preceding the other. This phenomenon 
leads to an individual approach in monitoring glaucoma, sometimes following a 
patient with measurements of structure, and sometimes with measurements of 
function. We have shown that SLP is especially an essential tool in diagnosing 
glaucoma in eyes converting from ocular hypertension (Chapter 3). Apparently, 
SLP is more sensitive in diagnosing early glaucoma in eyes converting from ocular 
hypertension than SAP. This is confirmed by older studies in the early nineties.28;29 
We therefore advise an ophthalmologist to consider to implement SLP, or another 
measurement of structure, in this individual approach in daily care to monitor eyes 
with ocular hypertension to diagnose early glaucoma.
Glaucoma with only structural defects and no functional defects (yet) is known as 
preperimetric glaucoma. This group of glaucoma will enlarge when monitoring is 
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more and more done by structural measurements, such as SLP or OCT. But in the 
long term, compared to waiting for it to become perimetric glaucoma, this earlier 
detection and proper treatment of preperimetric glaucoma, will ideally lead to less 
severe glaucoma and therefore to less visual disability.
Optical coherence tomography
Spectral domain OCT (SD-OCT) is commercially available since 2006. Since then, 
it is increasingly used in daily glaucoma care. Especially now that SLP technology 
is no longer commercially manufactured, SD-OCT becomes more and more the 
standard technique to measure structural glaucomatous loss. Interestingly, to our 
knowledge, measuring the RNFL thickness around the ONH by SD-OCT currently 
does not consistently outperform other available techniques in their diagnostic 
accuracy, such as SLP and CSLO.20;30-33 On the other hand, newer technologies 
lead to new insights. In this thesis, we presented two new insights in glaucoma 
due to the use of SD-OCT. Firstly, we presented a newly described phenomenon: 
a focal microcystic schisis of the RNFL in glaucomatous eyes, located in an area 
of a pre-existing glaucomatous RNFL defect, suggesting that this phenomenon 
is associated with glaucomatous wedge defects of the RNFL (Chapter 7). Several 
recent studies presented cases with peripapillary retinoschisis, imaged with SD-
OCT.34-39 All studies showed a relation between the retinoschisis and the presence 
of glaucoma. The pathophysiological mechanism is still speculated on: most agree 
on the presence of fluid in or between the retinal layers. The origin of this fluid 
remains unclear. It might be of vitreous origin, as Kahook et al. suggested37, or the 
fluid might be cerebrospinal fluid, entering the retina through the lamina cribrosa 
along the tiny canals created by the pathological absence of the nerve fibers. Evi-
dently, this interesting phenomenon needs further study to analyse its underlying 
pathophysiologic mechanisms and its relation to glaucoma.
The second new observation that we made with the SD-OCT was not only that 
the RNFL thins in glaucoma, but also that the optical scattering properties of the 
RNFL change due to glaucoma. We presented a newly described parameter, the 
attenuation coefficient (µatt), which quantifies the optical scattering properties of 
retinal layers. Up till now, the only parameter related to the RNFL was its thickness. 
The model we described, is based on the reflectivity of the RNFL and the RPE, as 
well as on the interaction between light and the tissue and also on the thickness 
of the RNFL. We hypothesized that µatt indirectly measures the nerve fiber den-
sity of the RNFL. The attenuation coefficient of the RNFL in SD-OCT images was 
lower in glaucomatous eyes than in healthy eyes and it decreased with increasing 
disease severity. Additionally, we found that the correlation of µatt with standard 
automated perimetry (SAP) was comparable to that of SLP and CSLO with SAP.40-43 
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We speculate that the reduced µatt of the RNFL in SD-OCT images in glaucoma-
tous eyes might serve as a discriminating feature for structural changes. Further 
analyses of this parameter might also potentially lead to new scientifical insights in 
the pathofysiological mechanism of the development of glaucoma. Future studies 
are needed to clarify the role of the µatt of the RNFL in diagnosing and following 
glaucoma with SD-OCT, potentially leading to a new method to quantify glaucoma 
in SD-OCT images in daily practice.
Progression analysis
Currently, every commercially available device measuring functional or structural 
glaucomatous damage, provides analyses of progression. These progression anal-
yses are helpful to diagnose conversion to glaucoma in eyes with ocular hyperten-
sion, as is described in Chapter 3. In our study, measurements of structure (SLP) 
showed conversion to glaucoma earlier than measurements of function (SAP) did. 
On the other hand, in progressing glaucomatous eyes, SAP flagged glaucomatous 
progression much more often than ophthalmologists did, when observing struc-
tural change based on the ONH, as described in Chapter 6. Because of this poor 
agreement between structure and function21-26 in monitoring and detecting glau-
comatous progression, as in diagnosing glaucoma, up till now no gold standard 
has been determined. In daily practice, determining the rate of progression (RoP) 
is an important part of monitoring glaucoma, usually based on SAP. The RoP is the 
loss of RGCs and visual function compared to the decay based on aging alone 
and, amongst other parameters, one of the pillars of glaucoma management. The 
conflicting results on detecting glaucomatous progression by different techniques 
hampers the justified use of RoP in daily practice.
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fuTure PersPeCTIves
Currently, the future in diagnosing and monitoring glaucoma is directed to SD-OCT, 
or even its successors. SLP and CSLO are both still used in daily glaucoma practice. 
Nevertheless, nowadays the focus has increasingly been shifted towards SD-OCT. 
The main advantage of SD-OCT is its multifunctional use in ophthalmology. Not 
only glaucoma, but also many other retinal abnormalities are currently detected 
and followed by SD-OCT. Also the ongoing development of the technique prom-
ises increased quality of images and analyses in the near future.
Development of new analyses
Until recently, the main structural parameter in measuring glaucoma was the thick-
ness of the peripapillary RNFL. Nowadays, also the thickness of the macular gan-
glion cell layer & inner plexiform layer together combined with the RNFL, called the 
ganglion cell complex (GCC), is incorporated in commercially available analyses. 
This analysis is based on the knowledge that up to 50% of the RGCs are located 
in the macular region.44 These layers are potentially easier to image, because the 
RGC body has a larger diameter than its axons and the macular area is charac-
terised by less intersubject variability.45 Analyses of the GCC therefore potentially 
detect thinning more easily than by measuring the peripapillary RNFL thickness.46 
Various studies have shown a comparable diagnostic sensitivity between these 
2 mentioned parameters.45 Currently, these macular parameters do not seem to 
outperform the RNFL thickness, but they might be of additional value in patients 
with anatomical variations leading to erroneous peripapillary RNFL measurements, 
such as high myopia, peripapillary atrophy or a tilted disc.45
Another newly developed analysis in SD-OCT is a neuroretinal rim analysis, 
measuring the minimal rim width, defined as the shortest distance between the 
Bruchs membrane opening and the inner limiting membrane, averaged around the 
optic disc.47;48 With further developing techniques, both approaches are promising. 
These analyses have already been implemented in some commercially available 
devices.
Development of new OCT techniques
Swept-source OCT provides higher resolution images with enhanced depth 
imaging due to the use of a 1050nm light source and a higher scanning speed. 
Currently, the first commercial device (DRI-OCT1 Atlantis system, Topcon, Tokyo, 
Japan) has become available. Studies have shown SS-OCT not to outperform SD-
OCT in diagnosing glaucoma by measuring RNFL thickness49 and the thickness of 
the GCC50. On the other hand, SS-OCT shows promising results in measuring other 
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parameters in glaucoma, such as anatomical changes of the lamina cribrosa51-53 and 
the anterior chamber angle54;55, because of its enhanced depth imaging.
Polarisation sensitive OCT combines measuring the birefringence of the RNFL 
with measuring the RNFL thickness by OCT.56-58 A third development in the tech-
nique of OCT, is the introduction of adaptive optics (AO). AO increases imaging 
resolution and sensitivity. It has been incorporated into CSLO, and also into OCT. 
This AO-OCT provides analyses of the individual retinal nerve fiber bundles, en-
abling more detailed analysis of the loss of these bundles due to glaucoma. 59
Pitfalls of OCT and technical development
A worrisome aspect of the current development of SD-OCT is the many com-
mercial developers creating an SD-OCT device. To date, more than 10 different 
SD-OCTs are commercially available, all with their own hardware and software. The 
differences between these devices, with their own hardware and software algo-
rithms, makes it impossible to interchange data. Every company creates their own 
analyses, image processing and scan protocols, as well as the earlier described 
new analyses. No standardisation has been achieved between these different SD-
OCTs. Therefore, scans and their interpretations are not comparable to each other.
The quick development in the past few years and most probably also in the up-
coming years leads to the question whether the measurements of a current device 
still are useful and backward compatible in the near future, when newer software, 
scan protocols, image processing and analyses have been developed. This ques-
tion is often asked by general ophthalmologists in case of several ophthalmologic 
devices, used in daily care, but is a very essential question in chronic diseases such 
as glaucoma. Long term analyses measuring progression need to be backward 
compatible and stable for several years. Also long term follow up trials are severely 
hampered by this problem of development and (absence of) backward compatibil-
ity of devices, as illustrated by the data presented in Chapter 3 & 4, which has led 
to a severe decline of useful data. It is an important challenge for the developers 
of these devices to implement innovation in the current devices used for follow up 
without hampering accessibility of the already collected data to newly developed 
analyses.
Challenges
With every currently available imaging technique, it remains a challenge to detect 
and follow glaucoma. Firstly in diagnosing glaucoma, one needs to combine the 
outcome of several measurements in order to decide whether or not glaucoma 
is present. This is a challenge, because of the large biological variation within 
healthy eyes and the inherent overlap with glaucomatous eyes. Between trials, 
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glaucoma or its progression are defi ned differently, hampering comparison of the 
outcomes of these trials. But it even makes it harder for any clinician to translate 
these outcomes to the daily care of glaucoma patients. Also choosing the type of 
measurements in daily practice to diagnose glaucoma, is a challenging task for an 
ophthalmologist. Should you just measure IOP, look at the ONH and do visual fi eld 
testing? Or does imaging indeed lead to an earlier diagnosis of glaucoma? Based 
on our studies, we advise to combine functional and structural measurements in 
diagnosing early glaucoma. On the other hand, in daily practice this might not 
always be possible due to practical and fi nancial reasons. Up till now, no strict 
consensus has been achieved on how exactly to diagnose and monitor glaucoma. 
This encourages ophthalmologists to diagnose and treat every individual patient 
by an individual approach.
In monitoring glaucoma, the most challenging issue is implementing the ongo-
ing development of techniques into the follow-up measurements over many years, 
without losing information. This chronic and usually slowly progressing disease 
requires techniques that are robust over time, as well as sensitive and specifi c. 
Whether or not to speak of progressing glaucoma is also an everyday challenge, 
depending on the types of measurements and the prudence or awareness of the 
ophthalmologist.
The absence of a strict consensus in diagnosing and monitoring glaucoma 
encourages an ophthalmologist to create an individual approach based on scien-
tifi cally-based protocols, experience and gut feeling. Diagnosing and monitoring 
glaucoma is an everyday complex challenge!
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Glaucoma is a heterogeneous group of progressive optic neuropathies charac-
terised by an accelerated degeneration of retinal ganglion cells (RGCs) and their 
axons, resulting in a typical appearance of the optic nerve head and a matching 
pattern of irreversible visual field loss. Worldwide, approximately 12% of all blind-
ness is due to glaucoma, which makes it the second leading cause of blindness. 
The most important risk factor is an increased intraocular pressure (IOP). In eyes 
with ocular hypertension, the IOP is increased without an optic neuropathy and 
visual field loss. The higher the IOP, the higher the risk of developing glaucoma. 
The IOP is currently the only factor that can be altered therapeutically. Lowering 
the IOP has been shown to slow down the progression of glaucoma.
To date, there is still no technique that measures the exact nature of the disease 
(the death of the RGCs and their axons). All techniques developed in the past de-
cades indirectly measure the functional and structural loss. In measuring glaucoma, 
the function of the eye is determined by measuring the visual field by perimetry. 
Several types of perimetry have been developed to measure the functional glauco-
matous loss. The structural loss due to glaucoma is determined by measuring the 
optic nerve head (ONH), which changes due to loss of RGCs and its axons, leading 
to a typical cupping of the ONH and the subsequent loss or thinning of the retinal 
nerve fiber layer. These structural changes are currently measured by several imag-
ing techniques, such as optical coherence tomography (OCT), confocal scanning 
laser ophthalmoscopy (CSLO) and scanning laser polarimetry (SLP).
The objective of the research presented in this thesis was to evaluate various 
techniques used in daily glaucoma practice to diagnose and monitor glaucoma.
In chapter 2, we compared 2 types of perimetry, standard automated perimetry 
(SAP), which is mainly used in daily care, and short wavelength automated perim-
etry (SWAP). SWAP had been claimed to predict conversion to glaucoma 3-4 years 
before SAP defects occur. Our purpose was to compare the moment of glauco-
matous conversion between SWAP and SAP in a large group of eyes with ocular 
hypertension. Our results did not support the notion that SWAP generally predicts 
conversion to glaucoma in SAP. Instead, SAP appeared to be at least as sensitive 
to conversion as SWAP in a large majority of eyes.
In chapters 3 & 4, we presented the results of a large randomised controlled 
trial into ocular hypertension and the effect of betablockers to prevent eyes from 
converting to glaucoma. Chapter 3 presented the rate of conversion from ocular 
hypertension to glaucoma defined by progression analyses on visual fields and 
SLP. SLP flagged conversion to glaucoma earlier than SAP in the large majority 
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of cases, potentially leading to earlier treatment preventing further progression 
to moderate or severe glaucoma. In Chapter 4, we presented the effect of topi-
cal beta-blockers on the rate of conversion of ocular hypertension to glaucoma, 
using the definition of conversion as presented in Chapter 3. This study showed 
a higher rate of conversion to glaucoma in ocular hypertensive eyes treated with 
beta-blockers, as well as with placebo eye drops, than other trials have described 
before. We showed that, in general, beta-blockers do not prevent eyes with ocular 
hypertension from converting to glaucoma.
In Chapter 5 & 6, we presented data on judging optic discs by professional 
glaucoma caregivers by assessing stereoscopic ONH photographs in diagnosing 
(Chapter 5) and monitoring (chapter 6) glaucoma. Firstly in Chapter 5, we assessed 
the ability of ophthalmologists across Europe to match stereoscopic photographs 
of various optic discs to their corresponding visual fields, from a selection of visual 
fields of varying severity. European ophthalmologists correctly matched stereo-
scopic optic disc photographs to their corresponding visual field in only approxi-
mately 59% of cases. In most mismatches, the clinicians overestimated the visual 
field damage. Apparently, because of their poor agreement, both clinical ONH 
judgment and evaluation of visual field test results remain important mainstays in 
daily clinical care. In Chapter 6, we determined the association between glaucoma 
progression in SAP and clinical assessment of stereoscopic ONH photographs. It 
also investigated any differences between various eye-care professionals in their 
ability to detect progression on sequential stereoscopic ONH photographs. We 
found a poor agreement between clinical assessment of serial stereoscopic ONH 
photographs and progression analysis on visual fields in glaucoma. In general, 
glaucoma specialists judged ONH photographs slightly more consistently than did 
less experienced eye care professionals.
In Chapter 7 & 8 we presented the newest commercially available technique to 
assist clinicians to diagnose and monitor glaucoma, the OCT. New techniques lead 
to new insights. Chapter 7 presented a newly described phenomenon in glaucoma-
tous eyes. We showed 7 cases with a transient focal microcystic schisis of the retinal 
nerve fiber layer (RNFL) in glaucomatous eyes in images obtained with spectral 
domain OCT (SD-OCT). Our data suggest that this phenomenon is associated with 
glaucomatous wedge defects in the RNFL. We compared the OCT-images with 
other techniques measuring glaucoma and this phenomenon was best observed 
with SD-OCT and it was absent in healthy eyes. Further research will be required to 
explore its course and its pathogenesis.
In chapter 8, we presented the first results of a newly developed parameter in 
OCT, the optical attenuation coefficient. In this chapter, we demonstrated the ef-
fect of glaucoma on the optical attenuation coefficient of the RNFL in SD-OCT 
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images. The measurements clearly demonstrated that the attenuation coeffi cient 
of the RNFL decreased with increasing disease severity. Future studies are needed 
to clarify the role of the attenuation coeffi cient of the RNFL in diagnosing and 
following glaucoma with SD-OCT, potentially leading to a new method to quantify 
glaucoma in SD-OCT images.
In summary, we evaluated various techniques used in daily glaucoma practice 
to diagnose and monitor glaucoma. SAP remains an important mainstay in daily 
glaucoma care, whereas SWAP turned out to be less sensitive than SAP. Accurately 
measuring structural change due to glaucoma remains a challenging goal. While 
SLP and CSLO have proven their additional value to the clinical assessment of the 
ONH, which, however, still remains challenging in ophthalmic care, the general 
focus of structural measurements for glaucoma has shifted towards SD-OCT. It has 
been shown to provide comparable diagnostic accuracy to the other structural 
measurements. In addition, SD-OCT allows the development of other types of 
measures in glaucoma than only the thickness of the RNFL, such as measures of 
the morphology of the ONH or the attenuation coeffi cient of the RNFL. SD-OCT 
is a promising technique with its ongoing technical development and the creation 
of new parameters, leading to a broader view on glaucoma and therefore to new 
insights. With the complexity of defi ning glaucoma and the ongoing current tech-
nical development, diagnosing and monitoring glaucoma is an everyday complex 
challenge!
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Glaucoom is een heterogene groep van progressieve aandoeningen van de oog-
zenuw gekenmerkt door een versneld verlies van retinale ganglioncellen (RGCs) en 
hun axonen, waardoor er een typisch uiterlijk van de oogzenuw en een bijpassend 
patroon van onomkeerbare gezichtsvelduitval ontstaat. Wereldwijd wordt ongeveer 
12% van alle blindheid veroorzaakt door glaucoom, wat het de tweede belangrijkste 
oorzaak van blindheid maakt. De belangrijkste risicofactor is een verhoogde intra-
oculaire druk (IOD). In ogen met oculaire hypertensie is de IOD verhoogd zonder 
aantasting van de oogzenuw en gezichtsvelduitval. Hoe hoger de IOD, hoe hoger 
het risico op het ontwikkelen van glaucoom. De IOD is momenteel de enige factor 
die kan worden beïnvloed met behandeling. Het is aangetoond dat het verlagen van 
de IOD de achteruitgang (progressie) van glaucoom doet vertragen.
Tot op heden is er nog geen techniek die de exacte aard van de ziekte (de dood 
van de RGCs en hun axonen) meet. Alle technieken die in de afgelopen decennia zijn 
ontwikkeld, meten indirect de functionele en structurele schade. Bij het meten van 
glaucoom wordt de functie van het oog bepaald door het gezichtsveld, dat wordt ge-
meten met behulp van perimetrie. Er zijn verschillende soorten perimetrie ontwikkeld 
om functionele schade ten gevolge van glaucoom te meten. De structurele schade 
als gevolg van glaucoom wordt bepaald door het meten van de oogzenuw (papil), die 
door verlies van RGCs en axonen verandert, wat leidt tot een typische ‘excavatie’ van 
de papil en het daaropvolgende verlies of verdunning van de retinale zenuwvezel-
laag. Deze structurele veranderingen kunnen worden gemeten door verscheidene 
beeldvormende technieken, zoals optische coherentie tomografie (OCT), confocale 
scanning laser ophthalmoscopie (CSLO) en scanning laser polarimetrie (SLP).
Het doel van het in dit proefschrift gepresenteerde onderzoek was om de ver-
schillende technieken te evalueren die in de dagelijkse praktijk worden gebruikt 
om glaucoom te diagnosticeren en monitoren.
In hoofdstuk 2 hebben we twee soorten perimetrie met elkaar vergeleken, i.e. stan-
daard automatische perimetrie (Standard Automated Perimetry, SAP), die vooral 
wordt gebruikt in de dagelijkse glaucoomzorg en Short-Wavelength Automated 
Perimetry (SWAP; in Nederland ook wel blauw-geel perimetrie genoemd). Van 
SWAP is beweerd dat het de conversie naar glaucoom 3-4 jaar eerder voorspelt 
dan dat SAP afwijkingen laat zien. Ons doel was om het moment van conversie 
naar glaucoom tussen SWAP en SAP te vergelijken in een grote groep van ogen 
met oculaire hypertensie. Onze resultaten ondersteunden niet de overtuiging dat 
SWAP conversie naar glaucoom in SAP voorspelt. In plaats daarvan bleek SAP 
minstens even gevoelig voor conversie als SWAP in verreweg de meeste ogen.
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In hoofdstuk 3 & 4 hebben we de resultaten van een grote gerandomiseerde studie 
gepresenteerd naar oculaire hypertensie en het effect van topicale bètablokkers in 
het voorkomen van het converteren naar glaucoom. Hoofdstuk 3 presenteerde het 
percentage conversie van oculaire hypertensie naar glaucoom, gedefinieerd door 
de progressie-analyses van gezichtsvelden en SLP. SLP detecteerde conversie naar 
glaucoom eerder dan SAP in de grote meerderheid van de gevallen, wat in potentie 
kan leiden tot het eerder behandelen om verdere progressie tot matig of ernstig 
glaucoom te voorkomen. In hoofdstuk 4, presenteerden we het effect van topicale 
bètablokkers op het percentage conversie van oculaire hypertensie naar glaucoom, 
met behulp van de definitie van conversie zoals gepresenteerd in hoofdstuk 3. Deze 
studie toonde een hoger percentage conversie naar glaucoom in ogen met oculaire 
hypertensie behandeld met bètablokkers, evenals met placebo oogdruppels, dan 
andere studies eerder beschreven. We toonden aan dat in het algemeen, bètablok-
kers ogen met oculaire hypertensie niet beschermen tegen conversie naar glaucoom.
In hoofdstuk 5 & 6 presenteerden we de uitkomsten van 2 studies naar het be-
oordelen van de oogzenuw door professionele glaucoom-zorgverleners, gebruik 
makend van stereoscopische foto’s van de oogzenuw bij het diagnosticeren 
(hoofdstuk 5) en monitoren (hoofdstuk 6) van glaucoom. In hoofdstuk 5 onderzoch-
ten we het vermogen van oogartsen in heel Europa om stereoscopische foto’s van 
verschillende oogzenuwen te koppelen aan de bijbehorende gezichtsvelden, door 
te kiezen uit een selectie van gezichtsvelden van verschillende ernst van glaucoom. 
Europese oogartsen hebben in slechts ongeveer 59% van de gevallen de stereo-
scopische foto van de oogzenuw correct gekoppeld aan het corresponderende 
gezichtsveld. In de meeste mismatches overschatte de arts het gezichtsvelduitval. 
Blijkbaar, vanwege hun slechte overeenkomst zullen zowel het klinische beoordelen 
van de oogzenuw als de evaluatie van gezichtsvelduitval belangrijke pijlers blijven 
van het beoordelen van de ernst van glaucoom in de dagelijkse klinische zorg. 
In hoofdstuk 6 hebben we de associatie tussen progressie op het gezichtsveld 
en de klinische beoordeling van achteruitgang van de oogzenuw met behulp van 
stereoscopische foto’s onderzocht. Ook zijn eventuele verschillen bekeken tussen 
de diverse oogheelkundige professionals in hun vermogen om progressie te de-
tecteren op sequentiële stereoscopische foto’s van de oogzenuw. We vonden een 
slechte overeenkomst tussen de klinische beoordeling van de oogzenuw middels 
de seriële stereoscopische foto’s en progressie analyse van de gezichtsvelden in 
glaucoom. In het algemeen, glaucoom specialisten beoordeelden de oogzenuw 
iets consequenter dan wat minder ervaren oogzorg professionals.
In hoofdstuk 7 & 8 presenteerden we de nieuwste commercieel beschikbare 
techniek om clinici te helpen bij het diagnosticeren en monitoren van glaucoom, 
de OCT. Nieuwe technieken leiden tot nieuwe inzichten. Hoofdstuk 7 presen-
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teerde een nieuw beschreven verschijnsel op OCT in ogen met glaucoom. We 
toonden 7 gevallen met een tijdelijke focale microcysteuze schisis van de retinale 
zenuwvezellaag (retinal nerve fi ber layer, RNFL) in ogen met glaucoom in spectraal-
domein OCT (SD-OCT). Onze data suggereren dat dit fenomeen geassocieerd is 
met glaucomateuze wig-defecten in de RNFL. We vergeleken de OCT-beelden 
met andere technieken waarmee men glaucoom kan meten en het bleek dat dit 
fenomeen het beste werd waargenomen met SD-OCT; deze microcysteuze schisis 
zagen we niet in gezonde ogen. Verder onderzoek zal nodig zijn om het beloop en 
de pathogenese verder te onderzoeken.
In hoofdstuk 8, presenteerden we de eerste resultaten van een nieuw ontwik-
kelde parameter in OCT, de attenuatie-coëffi ciënt. In dit hoofdstuk hebben we 
het effect aangetoond van glaucoom op de attenuatie-coëffi ciënt van de RNFL in 
SD-OCT metingen. De metingen laten duidelijk zien dat de attenuatie-coëffi ciënt 
van de RNFL afneemt met het toenemen van de ernst van de ziekte. Toekomstige 
studies zijn nodig om meer inzicht te krijgen in de rol van de attenuatie-coëffi ciënt 
van de RNFL in het diagnosticeren en monitoren van glaucoom, mogelijk leidend 
tot een nieuwe methode om glaucoom te kwantifi ceren in SD-OCT beelden.
Samengevat evalueerden we verschillende technieken in de dagelijkse glau-
coomzorg om glaucoom te diagnosticeren en te monitoren. SAP blijft een belan-
grijke steunpilaar in de dagelijkse glaucoomzorg, terwijl SWAP minder gevoelig 
bleek te zijn dan SAP. Nauwkeurig meten van structurele veranderingen als gevolg 
van glaucoom blijft een uitdagend doel. Hoewel SLP en CSLO hun waarde heb-
ben bewezen in de klinische beoordeling van de oogzenuw en de RNFL, is de 
algemene aandacht voor het structureel meten van glaucoom verschoven naar 
SD-OCT. Er blijkt vooralsnog een vergelijkbare diagnostische nauwkeurigheid ten 
opzichte van de andere structurele metingen. Daarnaast faciliteert de SD-OCT 
de ontwikkeling van nieuwe parameters voor het meten van glaucoom dan alleen 
de dikte van de RNFL, zoals het meten van de morfologie van de ONH of de 
attenuatie-coëffi ciënt van de RNFL. SD-OCT is een veelbelovende techniek met 
een voortdurende technische ontwikkeling en met de ontwikkeling van nieuwe pa-
rameters, wat leidt tot een bredere kijk op glaucoom en dus tot nieuwe inzichten. 
Met de complexiteit van het defi niëren van glaucoom en de voortdurende huidige 
technische ontwikkeling, is het diagnosticeren en monitoren van glaucoom een 
alledaagse complexe uitdaging!
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dankwoord
Promoveren is als het bewandelen van een labyrint: wie dat ene pad van promo-
veren betreed, is op weg naar de uiteindelijke bestemming: de promotie. Dit pad 
heeft vele wendingen, steeds weer onzichtbaar waar de weg heen gaat. Af en 
toe gaat het vlak langs het einddoel, om er weer weg van te geraken; een proeve 
van vastberadenheid en doorzettingsvermogen. De weg zelf leidt tot inzichten, 
minstens net zo belangrijk als het einddoel.
Mijn pad is lang geweest en heeft ook vele wendingen gekend. Nu is het zover 
dat het einddoel bereikt is. Zonder de weg geen einddoel. En deze weg heb ik 
bewandeld met velen naast mijn zijde, mij inspirerend, motiverend, vergezellend, 
leidend (en soms afleidend) en volgend. Jullie hebben mijn promotieweg mede 
kleur gegeven, verlicht en het waard gemaakt te bewandelen, waarvoor allen dank! 
Een aantal mensen wil ik in het bijzonder danken:
Allereerst mijn co-promotor Hans Lemij. Het is inmiddels ruim 10 jaar geleden dat 
ik als co-assistent een ochtend met jouw spreekuur meekeek. Die ochtend raakten 
we in gesprek over oogheelkunde en onderzoek en heb je mij geïnspireerd een 
ander pad te bewandelen dan ik tot dan toe voor ogen had. Vanaf toen heb jij 
mij zijdelings gevolgd op mijn weg naar waar ik nu sta. Je hebt me met je geduld, 
vertrouwen en gidsend vermogen af en toe de weg gewezen, en me vooral mijn 
eigen pad laten volgen. Ik vind je een inspirerend arts, een creatief mens en een 
kritisch en kundig wetenschapper. Dank voor jouw zijn op mijn pad.
Mijn promotor Prof. Jan van Meurs. Ook jou heb ik als co-assistent voor het eerst 
ontmoet tijdens je spreekuren en operaties waarbij je pigmentblad-transplantaties 
uitvoerde. Ik dacht dat dit de normaalste zaak van de wereld was binnen de 
oogheelkunde, echter dit was toch wat onderschat. Je bescheidenheid en ont-
spannen houding leidde ertoe dat ik er later pas achter kwam dat dit jouw eigen 
pionierswerk was. Dank voor het zijn van een inspiratie hierin. Ik ben vereerd jou als 
promotor te mogen hebben.
De leden van de leescommissie, Prof. J.R. Vingerling, Prof. N.M. Jansonius en Prof. 
C.A.B. Cremers dank ik hartelijk voor het kritisch beoordelen van mijn proefschrift 
en het plaatsnemen in mijn commissie.
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Deze studie was niet mogelijk geweest zonder de jarenlange toewijding van alle 
aan de studie vrijwillig deelnemende mensen. Met veel plezier en gezelligheid heb 
ik menig uurtjes met jullie gevuld voor de metingen.
Koen Vermeer, dank je wel voor je geduld en je duidelijke uitleg van die inge-
wikkelde fysische principes aan mij als leek. Je kritische niet-medische blik was 
verhelderend in onze artikelen. Dank voor het zijn van zo’n prettige persoonlijkheid 
en een fijne collega. Nic Reus en Thomas Colen, jullie hebben de basis gelegd 
voor deze jarenlange studie en een fantastische database gecreëerd. Jullie 
conscentieuze werk en daarnaast jullie kritisch en heldere oog voor detail bij de 
artikelen waardeer ik enorm. I would like to thank all European co-authors of the 
ESAFAT-group and all ophthalmologists participating in this trial for their share in 
our publication. 
Alle mensen van het ROI wil ik bedanken voor de prettige tijd die ik heb ervaren 
tijdens mijn onderzoek. In het bijzonder Netty Dorresteijn. Ik wil je bedanken 
voor je kritische blik en begeleiding in het wel en wee van onderzoeksland om 
zo onze studie binnen de gegeven kaders te laten verlopen. Johannes de Boer 
& Rene Wubbels, dank jullie wel voor het vooral op de achtergrond meewerken 
aan het vorderen van het onderzoek. Annemiek, Carolien, Jetty & Marja: dames, 
dank jullie wel voor jullie ondersteuning, zowel professioneel als persoonlijk! Alle 
mede-onderzoekers: dank voor het zijn van een klankbord, inspiratie en voor alle 
gezelligheid! Leonieke, Esther, Maartje, Myrthe & Toine, weten jullie nog wat een 
ommezwaai het was om bij de oprichting van het ROI van de donkere kamertjes 
in het OZR naar de met zon overgoten kamers te gaan met de Rotterdam skyline 
als uitzicht? Dank jullie wel dat ik dat met jullie vanuit hetzelfde perspectief heb 
mogen ervaren!
In het bijzonder wil ik Mieke Triesscheijn bedanken. Mieke, zo warm, conscentieus 
en doorzettend als je altijd bent geweest. Je werkte zo hard, cijferde jezelf vaak 
weg voor anderen; eigenschappen waardoor je in je werk enorm gewaardeerd 
werd. Ik heb je gelukkig ook persoonlijk mogen leren kennen als een fijne, lieve 
vrouw en het is een enorm gemis dat je niet meer bij ons bent.
Alle collega’s van het Oogziekenhuis Rotterdam wil ik bedanken voor hun inte-
resse in mijn onderzoek. Daarnaast wil ik de afdeling Perimetrie en Fotografie (de 
huidige Beeld- & Functie-afdeling) bedanken voor hun vele jaren trouwe hulp. In 
het bijzonder Marjo van der Horst, Gerard de Graaf, Melania Simileer, Cees van 
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Ostende, dank voor jullie inzet. Dank aan de MID/ICT voor het telkens maar weer 
draaiende krijgen van computers, software en apparaten. 
Alle oogartsen en arts-assistenten wil ik bedanken voor hun jarenlange interesse 
in mijn promotie-onderzoek. In het bijzonder wil ik de glaucoomspecialisten Peter 
de Waard, Jelle de Vries, Antoinette Niessen, Jan-Geert Bollemeijer en Theo 
Nieuwendijk bedanken voor het aanleveren van patiënten, het delen van jullie 
onuitputtelijke kennis en het zijn van zo’n heterogene en daarmee elkaar aanvul-
lende groep!
Lieve Karin Littink & Jocelyn van Brakel, mijn paranimfen. Wat ben ik bevoorrecht 
dat ik jullie aan mijn zijde heb staan! Beiden met dezelfde bagage in onderzoeks-
land. Karin, ik bewonder je harde werken, je altijd oprechte interesse in anderen 
en je warme openheid. Het is fijn dat ik je altijd als collega zal hebben, al is de 
afstand straks wat groter. Jos, het is ons beiden dan toch gelukt! Ik ben blij dat ik 
je al die jaren al ken en ben trots op je dat je je doelen niet alleen nastreeft, maar 
ook bereikt, getuige je nieuwe baan!
Alle lieve vrienden en familie, het zal niet altijd en voor iedereen even duidelijk zijn 
geweest waar ik al die jaren toch mee bezig ben geweest. Desondanks heb ik altijd 
jullie steun mogen ervaren. Dank jullie wel daarvoor!
Lieve Alie, wat vind ik het fijn dan we 16 jaar geleden samen uit het hoge noorden 
naar Rotterdam zijn gegaan en nog steeds vriendinnen zijn. Ik wens dat we de tijd 
minstens nog zullen verdubbelen! Claire, ik heb bewondering voor hoe je staat en 
gaat voor je idealen, ondanks de mening van anderen. Lieve Mark & Sibrecht, wat 
vind ik het fijn dat jullie in mijn leven zijn gekomen. De vele avonden en wandelin-
gen met goede gesprekken zijn me dierbaar en ik wens ze nog vaak met jullie te 
mogen delen! 
Lieve Anne, Mirjam & Giuseppe, Sjoeke & Koos, Cor & Nel, Han, Maaike & Robert. 
Mijn lieve (schoon)familie, dank voor jullie blijvend vertrouwen in het slagen van 
mijn missie! Dank voor jullie soms kritische blik en onvoorwaardelijke steun. 
Lieve Gert en Tia. Papa en mama, dank jullie wel voor het zijn van een vast baken, 
al jullie vertrouwen en liefde. Jullie hebben me altijd de vrijheid en ruimte gegeven 
mijn eigen keuzes te maken, wat me heeft geleid tot hier.
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Lieve Ference, dit boekje was er nooit geweest zonder jou aan mijn zijde! Wat ben 
ik bevoorrecht jouw vrouw te zijn. Dank je wel voor jouw altijd blijvende vertrouwen 
in dit pad dat ik nu bewandeld heb, en voor je aansporing het steeds weer op te 
pakken. Dank je wel voor je onvoorwaardelijke liefde. Ik heb de eindbestemming 
bereikt! Vanaf nu ga ik dolgraag met jou en de jongens een nieuw pad in: wortelen 
op onze nieuwe plek. Ik kijk er erg naar uit om onze eigen plek van leven, rust en 
plezier te creëren! Ik hou van je. 
Lieve Lucas en Mels, m’n lieve schatten! Wat hebben jullie mijn leven verrijkt! Dank 
dat jullie in mijn leven zijn gekomen, om een heel stuk samen mijn levenspad te 
bewandelen. Lucas, je hebt de zin “ik ga aan het werk” je eigen gemaakt, omdat 
je het te vaak hebt gehoord. Ik zal het niet meer zeggen. Lieve jongens, dank voor 
het zijn van mijn spiegel. Ik hou van jullie, zielsveel!
De vraag ‘Hoe is het nou met je studie?’ van mensen die wellicht denken dat ik een 
eeuwige student ben, kan ik nu na vele jaren positief beantwoorden: ‘Het is klaar!’.
Josine van der Schoot
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